Professor Andrew Briggs
- Visiting Professor (School of Health & Wellbeing)
telephone:
01413305017
email:
Andrew.Briggs@glasgow.ac.uk
Hehta, Institute of Health & Wellbeing, 1 Lilybank Gardens, Glasgow G12 8RZ
https://orcid.org/0000-0002-0777-1997Publications
2024
Gögenur, M. et al. (2024) Time from colorectal cancer surgery to adjuvant chemotherapy – post hoc analysis of the SCOT trial. JAMA Surgery, 159(8), pp. 865-871. (doi: 10.1001/jamasurg.2024.1555) (PMID:38865139)
Robles-Zurita, J. A., Mcmeekin, N., Sullivan, F., Mair, F. S. and Briggs, A. (2024) Health economic evaluation of lung cancer screening using a diagnostic blood test: the Early detection of Cancer of the Lung Scotland (ECLS). Current Oncology, 31(6), pp. 3546-3562. (doi: 10.3390/curroncol31060261)
2023
Melville, C.A. et al. (2023) Predictors and moderators of the response of adults with intellectual disabilities and depression to behavioural activation and guided self-help therapies. Journal of Intellectual Disability Research, 67(10), pp. 986-1002. (doi: 10.1111/jir.13063) (PMID:37344986)
Breeze, P. R. et al. (2023) Guidance on the use of complex systems models for economic evaluations of public health interventions. Health Economics, 32(7), pp. 1603-1625. (doi: 10.1002/hec.4681) (PMID:37081811)
2022
McEwan, P., Darlington, O., Miller, R., McMurray, J. J.V. , Wheeler, D. C., Heerspink, H. J.L., Briggs, A. , Bergenheim, K. and Garcia Sanchez, J. J. (2022) Cost-effectiveness of dapagliflozin as a treatment for chronic kidney disease: a health-economic analysis of DAPA-CKD. Clinical Journal of the American Society of Nephrology, 17(12), pp. 1730-1741. (doi: 10.2215/CJN.03790322) (PMID:36323444)
Gumley, A. I. et al. (2022) The EMPOWER blended digital intervention for relapse prevention in schizophrenia: a feasibility cluster randomised controlled trial in Scotland and Australia. Lancet Psychiatry, 9(6), pp. 477-486. (doi: 10.1016/S2215-0366(22)00103-1)
Gumley, A. I. et al. (2022) Digital smartphone intervention to recognise and manage early warning signs in schizophrenia to prevent relapse: the EMPOWER feasibility cluster RCT. Health Technology Assessment, 26(27), (doi: 10.3310/hlze0479) (PMID:35639493) (PMCID:PMC9376801)
Kohli-Lynch, C. N., Lewsey, J. , Boyd, K. A. , French, D. D., Jordan, N., Moran, A. E., Sattar, N. , Preiss, D. and Briggs, A. H. (2022) Beyond 10-year risk: a cost-effectiveness analysis of statins for the primary prevention of cardiovascular disease. Circulation, 145(17), pp. 1312-1323. (doi: 10.1161/CIRCULATIONAHA.121.057631) (PMID:35249370) (PMCID:PMC9022692)
Cotton, S. et al. (2022) Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS). Trials, 23, 307. (doi: 10.1186/s13063-022-06226-8) (PMID:35422024) (PMCID:PMC9009490)
Xin, Y. , Gray, E., Robles-Zurita, J. A., Haghpanahan, H. , Heggie, R., Kohli-Lynch, C., Briggs, A. , McAllister, D. A. , Lawson, K. D. and Lewsey, J. (2022) From spreadsheets to script: experiences from converting a Scottish cardiovascular disease policy model into R. Applied Health Economics and Health Policy, 20(2), pp. 149-158. (doi: 10.1007/s40258-021-00684-y) (PMID:34671930)
2021
Hanna, C. R. et al. (2021) Three versus six months of adjuvant doublet chemotherapy for patients with colorectal cancer: a multi-country cost-effectiveness and budget impact analysis. Clinical Colorectal Cancer, 20(3), pp. 236-244. (doi: 10.1016/j.clcc.2021.04.001) (PMID:33992542)
Grieve, E. , Hesselgreaves, H., Wu, O. and Briggs, A. (2021) Bridging the Perceived Disconnect between Health Technology Assessment and Delivery Systems. 2021 World Congress on Health Economics, 12-15 Jul 2021.
Dick, K., Schneider, J. E., Briggs, A. , Lecomte, P., Regnier, S. A. and Lean, M. (2021) Mendelian randomization: estimation of inpatient hospital costs attributable to obesity. Health Economics Review, 11, 16. (doi: 10.1186/s13561-021-00314-2) (PMID:33990897) (PMCID:PMC8122556)
Sullivan, F. et al. (2021) Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging. European Respiratory Journal, 57(1), 2000670. (doi: 10.1183/13993003.00670-2020) (PMID:32732334)
Bouttell, J. , Briggs, A. and Hawkins, N. (2021) A toolkit of methods of development-focused health technology assessment. International Journal of Technology Assessment in Health Care, 37(1), e84. (doi: 10.1017/S0266462321000507)
Bouttell, J. , Hawkins, N. and Briggs, A. (2021) The thorny issue of value alignment: how development-focused health technology assessment can help find win–win situations for patients and healthcare systems and commercial investors. International Journal of Technology Assessment in Health Care, 37(1), e57. (doi: 10.1017/S026646232100026X) (PMID:33875040)
2020
Robles-Zurita, J. A., Briggs, A. , Rana, D. , Quayyum, Z., Oldroyd, K. G., Zeymer, U., Desch, S., de Waha-Thiele, S. and Thiele, H. (2020) Economic evaluation of culprit lesion only PCI vs. immediate multivessel PCI in acute myocardial infarction complicated by cardiogenic shock: the CULPRIT-SHOCK trial. European Journal of Health Economics, 21, pp. 1197-1209. (doi: 10.1007/s10198-020-01235-3) (PMID:33029668)
Xin, Y. , Davies, A., Briggs, A. , McCombie, L., Messow, C. M. , Grieve, E. , Leslie, W. S., Taylor, R. and Lean, M. E.J. (2020) Type 2 diabetes remission: 2 year within-trial and lifetime-horizon cost-effectiveness of the Diabetes Remission Clinical Trial (DiRECT)/Counterweight-Plus weight management programme. Diabetologia, 63, pp. 2112-2122. (doi: 10.1007/s00125-020-05224-2) (PMID:32776237) (PMCID:PMC7476973)
Bouttell, J. , Briggs, A. and Hawkins, N. (2020) A different animal? Identifying the features of health technology assessment for developers of medical technologies. International Journal of Technology Assessment in Health Care, 36(4), pp. 285-291. (doi: 10.1017/S0266462320000380)
Hájek, R., Gonzalez-McQuire, S., Szabo, Z., Delforge, M., DeCosta, L., Raab, M. S., Bouwmeester, W., Campioni, M. and Briggs, A. (2020) Novel risk stratification algorithm for estimating the risk of death in patients with relapsed multiple myeloma: External validation in a retrospective chart review. BMJ Open, 10(7), e034209. (doi: 10.1136/bmjopen-2019-034209) (PMID:32665382) (PMCID:PMC7365483)
McMeekin, N., Wu, O. , Germeni, E. and Briggs, A. (2020) How methodological frameworks are being developed: evidence from a scoping review. BMC Medical Research Methodology, 20, 173. (doi: 10.1186/s12874-020-01061-4) (PMID:32605535) (PMCID:PMC7325096)
Briggs, A. , Daniele, B., Dick, K., Evans, T. R. J. , Galle, P. R., Hubner, R. A., Lopez, C., Siebert, U. and Tremblay, G. (2020) Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma. British Journal of Cancer, 122(12), pp. 1754-1759. (doi: 10.1038/s41416-020-0817-7) (PMID:32265508) (PMCID:PMC7283323)
McMeekin, N., Geue, C. , Briggs, A. , Rombach, I., Li, H. K., Bejon, P., McNally, M., Atkins, B. L., Ferguson, J. and Scarborough, M. (2020) Cost-effectiveness of oral versus intravenous antibiotics (OVIVA) in patients with bone and joint infection: evidence from a non-inferiority trial. Wellcome Open Research, 4, 108. (doi: 10.12688/wellcomeopenres.15314.4)
Dick, K., Briggs, A. , Ohsfeldt, R., Sydendal Grand, T. and Buchs, S. (2020) A quality of life mapping function developed from a grass pollen sublingual immunotherapy trial to a tree pollen sublingual immunotherapy trial. Journal of Medical Economics, 23(1), pp. 64-69. (doi: 10.1080/13696998.2019.1649268) (PMID:31352853)
Gumley, A. et al. (2020) Early signs monitoring to prevent relapse in psychosis and promote well-being, engagement, and recovery: protocol for a feasibility cluster randomized controlled trial harnessing mobile phone technology blended with peer support. JMIR Research Protocols, 9(1), e15058. (doi: 10.2196/15058) (PMID:31917372)
2019
Iveson, T. et al. (2019) 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT. Health Technology Assessment, 23(64), (doi: 10.3310/hta23640) (PMID:31852579)
Tremblay, G., Westley, T., Forsythe, A., Pelletier, C. and Briggs, A. (2019) A criterion-based approach to systematic and transparent comparative effectiveness: a case study in psoriatic arthritis. Journal of Comparative Effectiveness Research, 8(15), pp. 1265-1298. (doi: 10.2217/cer-2019-0064) (PMID:31774340)
Xin, Y. , Davies, A., McCombie, L., Briggs, A. , Messow, C.-M. , Grieve, E. , Leslie, W.S., Taylor, R. and Lean, M.E.J. (2019) Type 2 diabetes remission: economic evaluation of the DiRECT/Counterweight‐Plus weight management programme within a primary care randomized controlled trial. Diabetic Medicine, 36(8), pp. 1003-1012. (doi: 10.1111/dme.13981) (PMID:31026353)
Devereux, G. et al. (2019) Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT. Health Technology Assessment, 23(37), pp. 1-146. (doi: 10.3310/hta23370)
Grieve, E. and Briggs, A. (2019) IDSI Reference Case work stream. F1000Research, 8, 803. (doi: 10.7490/f1000research.1116834.1)
Ward Thompson, C. et al. (2019) Enhancing health through access to nature: how effective are interventions in woodlands in deprived urban communities? A quasi-experimental study in Scotland, UK. Sustainability, 11(12), 3317. (doi: 10.3390/su11123317) (PMID:31844557) (PMCID:PMC6914372)
Welsh, P. et al. (2019) Cardiac troponin T and troponin I in the general population: comparing and contrasting their genetic determinants and associations with outcomes. Circulation, 139(24), pp. 2754-2764. (doi: 10.1161/CIRCULATIONAHA.118.038529) (PMID:31014085) (PMCID:PMC6571179)
Xin, Y. , Davies, A., McCombie, L., Briggs, A. , Messow, C.-M. , Grieve, E. , Leslie, W. S., Taylor, R. and Lean, M. E.J. (2019) Within-trial cost and 1-year cost-effectiveness of the DiRECT/Counterweight-Plus weight-management programme to achieve remission of type 2 diabetes. Lancet Diabetes and Endocrinology, 7(3), pp. 169-172. (doi: 10.1016/S2213-8587(18)30346-2) (PMID:30581081)
Li, H.-K. et al. (2019) Oral versus intravenous antibiotics for bone and joint infection. New England Journal of Medicine, 380(5), pp. 425-436. (doi: 10.1056/NEJMoa1710926) (PMID:30699315)
Somers, C., Chimonas, S., McIntosh, E. , Kaltenboeck, A., Briggs, A. and Bach, P. (2019) Using nominal group technique to identify key attributes of oncology treatments for a discrete choice experiment. MDM Policy and Practice, 4(1), (doi: 10.1177/2381468319837925) (PMID:30915400) (PMCID:PMC6429659)
Ward Thompson, C. et al. (2019) Health impacts of environmental and social interventions designed to increase deprived communities' access to urban woodlands: a mixed-methods study. Public Health Research, 7(2), (doi: 10.3310/phr07020)
2018
Robles-Zurita, J. A. et al. (2018) SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer. British Journal of Cancer, 119(11), pp. 1332-1338. (doi: 10.1038/s41416-018-0319-z) (PMID:30420616) (PMCID:PMC6265336)
Welsh, P. et al. (2018) Comparison between high-sensitivity cardiac troponin T and cardiac troponin I in a large general population cohort. Clinical Chemistry, 64(11), pp. 1607-1616. (doi: 10.1373/clinchem.2018.292086) (PMID:30126950)
Devereux, G. et al. (2018) Effect of theophylline as adjunct to inhaled corticosteroids on exacerbations in patients with COPD: a randomized clinical trial. JAMA: Journal of the American Medical Association, 320(15), pp. 1548-1559. (doi: 10.1001/jama.2018.14432) (PMID:30326124) (PMCID:PMC6233797)
Jahoda, A. et al. (2018) Behavioural activation versus guided self-help for depression in adults with learning disabilities: the BeatIt RCT. Health Technology Assessment, 22(53), (doi: 10.3310/hta22530) (PMID:30265239)
Dolph, M., Roy, A., Bhor, M., Hearnden, J., Kwon, C. S., Forsythe, A., Tremblay, G. and Briggs, A. (2018) A decision framework for treating chronic immune thrombocytopenia with thrombopoietin receptor agonists. Journal of Comparative Effectiveness Research, 7(8), (doi: 10.2217/cer-2018-0034) (PMID:29848048)
Annemans, L., Packard, C. J. , Briggs, A. and Ray, K. K. (2018) 'Highest risk-highest benefit' strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies. European Heart Journal, 39(27), pp. 2546-2550. (doi: 10.1093/eurheartj/ehx710) (PMID:29236976) (PMCID:PMC6047410)
Ford, T. J. et al. (2018) Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular Angina (CorMicA) stratified medicine clinical trial. American Heart Journal, 201, pp. 86-94. (doi: 10.1016/j.ahj.2018.03.010) (PMID:29803987) (PMCID:PMC6018570)
Gray, C. M. et al. (2018) Long-term weight loss following a randomised controlled trial of a weight management programme for men delivered through professional football clubs: the Football Fans in Training follow-up study. Public Health Research, 6(9), (doi: 10.3310/phr06090) (PMID:30035935)
Gray, C. M. et al. (2018) Long-term weight loss trajectories following participation in a randomised controlled trial of a weight management programme for men delivered through professional football clubs: A longitudinal cohort study and economic evaluation. International Journal of Behavioral Nutrition and Physical Activity, 15, 60. (doi: 10.1186/s12966-018-0683-3) (PMID:29954449) (PMCID:29954449)
Johnson, M. J., McSkimming, P., McConnachie, A. , Geue, C. , Millerick, Y., Briggs, A. and Hogg, K. (2018) The feasibility of a randomised-controlled trial to compare the cost-effectiveness of palliative cardiology or usual care in people with advanced heart failure: two exploratory prospective cohorts. Palliative Medicine, 32(6), pp. 1133-1141. (doi: 10.1177/0269216318763225) (PMID:29688127) (PMCID:PMC5967038)
McMurray, J. J.V. et al. (2018) Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction. Heart, 104(12), pp. 1006-1013. (doi: 10.1136/heartjnl-2016-310661) (PMID:29269379) (PMCID:PMC5992367)
Price, D.B. et al. (2018) Use of 'Low-Dose' Theophylline to Reduce Exacerbations of COPD: a Pragmatic Multicentre Randomised Placebo Controlled Trial. ATS 2018 International Conference, San Diego, CA, USA, 18-23 May 2018.
Shah, D., Driessen, M., Risebrough, N., Baker, T., Naya, I., Briggs, A. and Ismaila, A. S. (2018) Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective. Cost Effectiveness and Resource Allocation, 16, 17. (doi: 10.1186/s12962-018-0101-3) (PMID:29773969) (PMCID:PMC5946544)
Stollenwerk, B., Iannazzo, S., Akehurst, R., Adena, M., Briggs, A. , Dehmel, B., Parfrey, P. and Belozeroff, V. (2018) A decision-analytic model to assess the cost-effectiveness of etelcalcetide vs. cinacalcet. PharmacoEconomics, 36(5), pp. 603-612. (doi: 10.1007/s40273-017-0605-2) (PMID:29392552)
Iveson, T. J. et al. (2018) 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. Lancet Oncology, 19(4), pp. 562-578. (doi: 10.1016/S1470-2045(18)30093-7) (PMID:29611518) (PMCID:PMC5883334)
Brazier, J., Briggs, A. and Bryan, S. (2018) EQ-5D-5L: Smaller steps but a major step change? Health Economics, 27(1), pp. 4-6. (doi: 10.1002/hec.3627) (PMID:29411469)
Morton, A., Bach, P. B. and Briggs, A. (2018) Enhancing the value of the ASCO value framework. MDM Policy and Practice, 3(1), pp. 1-3. (doi: 10.1177/2381468318776223) (PMID:30288447) (PMCID:PMC6157426)
2017
Grieve, E. , Hesselgreaves, H., Wu, O. , Chalkidou, K., Ruiz, F., Smith, P., Li, R., Morris, L. and Briggs, A. (2017) The Value of Health Technology Assessment: a mixed methods framework. F1000Research, 6, 2171. (doi: 10.7490/f1000research.1115169.1)
Jahoda, A. et al. (2017) Comparison of behavioural activation with guided self-help for treatment of depression in adults with intellectual disabilities: a randomised controlled trial. Lancet Psychiatry, 4(12), pp. 909-919. (doi: 10.1016/S2215-0366(17)30426-1) (PMID:29153873) (PMCID:PMC5714593)
Hoogendoorn, M., Feenstra, T. L., Boland, M., Briggs, A. H. , Borg, S., Jansson, S.-A., Risebrough, N., Slejko, J. and Rutten-van Mölken, M. P.M.H. (2017) Prediction models for exacerbations in different COPD patient populations: comparing results of five large data sources. International Journal of Chronic Obstructive Pulmonary Disease, 12, pp. 3183-3194. (doi: 10.2147/COPD.S142378) (PMID:29138546)
Kohli-Lynch, C.N. , Boyd, K. , Briggs, A. and Delles, C. (2017) A Framework for the Cost-Effectiveness Analysis of Novel Biomarker Testing in Cardiovascular Disease. ISPOR 20th Annual European Congress, Glasgow, UK, 4-8 Nov 2017. A404-A405. (doi: 10.1016/j.jval.2017.08.040)
Leyland, A. H. , Ouédraogo, S., Nam, J., Bond, L., Briggs, A. H. , Gray, R., Wood, R. and Dundas, R. (2017) Evaluation of health in pregnancy grants in Scotland: a natural experiment using routine data. Public Health Research, 5(6), (doi: 10.3310/phr05060) (PMID:29035487)
McMeekin, N., Briggs, A. and Wu, O. (2017) Developing A Conceptual Modelling Framework For Economic Evaluation. ISPOR 20th Annual European Congress, Glasgow, UK, 4-8 Nov 2017. A754-A755. (doi: 10.1016/j.jval.2017.08.2120)
Quayyum, Z., Briggs, A. , Robles-Zurita, J., Oldroyd, K., Zeymer, U., Desch, S., de Waha, S. and Thiele, H. (2017) Protocol for an economic evaluation of the randomised controlled trial of culprit lesion only PCI versus immediate multivessel PCI in acute myocardial infarction complicated by cardiogenic shock: CULPRIT-SHOCK trial. BMJ Open, 7(8), e014849. (doi: 10.1136/bmjopen-2016-014849) (PMID:28821512) (PMCID:PMC5724099)
Morton, A., Adler, A. I., Bell, D., Briggs, A. , Brouwer, W., Claxton, K., Craig, N., Fischer, A., McGregor, P. and van Baal, P. (2017) Unrelated future costs and unrelated future benefits: reflections on NICE Guide to the Methods of Technology Appraisal. Health Economics, 25(8), pp. 933-938. (doi: 10.1002/hec.3366) (PMID:27374115)
Claes, J. et al. (2017) PATHway I: design and rationale for the investigation of the feasibility, clinical effectiveness and cost-effectiveness of a technology-enabled cardiac rehabilitation platform. BMJ Open, 7(6), e016781. (doi: 10.1136/bmjopen-2017-016781) (PMID:28667228) (PMCID:PMC5726129)
Briggs, A. H. et al. (2017) Development of the Galaxy Chronic Obstructive Pulmonary Disease (COPD) model using data from ECLIPSE: internal validation of a linked-equations cohort model. Medical Decision Making, 37(4), pp. 469-480. (doi: 10.1177/0272989X16653118) (PMID:27317436)
Exuzides, A. et al. (2017) Statistical modeling of disease progression for chronic obstructive pulmonary disease using data from the ECLIPSE study. Medical Decision Making, 37(4), pp. 453-468. (doi: 10.1177/0272989X15610781) (PMID:26449490)
Negrín, M. A., Nam, J. and Briggs, A. H. (2017) Bayesian solutions for handling uncertainty in survival extrapolation. Medical Decision Making, 37(4), pp. 367-376. (doi: 10.1177/0272989X16650669) (PMID:27281336)
Williams, C., Lewsey, J. D. , Briggs, A. H. and Mackay, D. F. (2017) Cost-effectiveness analysis in R using a multi-state modelling survival analysis framework: a tutorial. Medical Decision Making, 37(4), pp. 340-352. (doi: 10.1177/0272989X16651869) (PMID:27281337) (PMCID:PMC5424858)
Williams, C., Lewsey, J. D. , Mackay, D. F. and Briggs, A. H. (2017) Estimation of survival probabilities for use in cost-effectiveness analysis: a comparison of a multi-state modelling survival analysis approach with partitioned survival and Markov decision-analytic modelling. Medical Decision Making, 37(4), pp. 427-439. (doi: 10.1177/0272989X16670617) (PMID:27698003) (PMCID:PMC5424853)
Gumley, A. et al. (2017) A parallel group randomised open blinded evaluation of Acceptance and Commitment Therapy for depression after psychosis: pilot trial outcomes (ADAPT). Schizophrenia Research, 183, pp. 143-150. (doi: 10.1016/j.schres.2016.11.026) (PMID:27894822)
Crombie, I. K. et al. (2017) Modifying Alcohol Consumption to Reduce Obesity (MACRO): development and feasibility trial of a complex community-based intervention for men. Health Technology Assessment, 21(19), (doi: 10.3310/hta21190) (PMID:28414020)
Briggs, A. H. , Bhatt, D. L., Scirica, B. M., Raz, I., Johnston, K. M., Szabo, S. M., Bergenheim, K., Mukherjee, J., Hirshberg, B. and Mosenzon, O. (2017) Health-related quality-of-life implications of cardiovascular events in individuals with type 2 diabetes mellitus: A subanalysis from the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-TIMI 53 trial. Diabetes Research and Clinical Practice, 130, pp. 24-33. (doi: 10.1016/j.diabres.2016.12.019) (PMID:28554140)
Sullivan, F.M. et al. (2017) Detection in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer using the EarlyCDT®-Lung Test (ECLS): study protocol for a randomized controlled trial. BMC Cancer, 17, 187. (doi: 10.1186/s12885-017-3175-y) (PMID:28284200) (PMCID:PMC5346215)
Grieve, E. and Briggs, A. (2017) A Methodological Approach for Measuring the Impact of HTA. Technical Report. F1000Research. (doi: 10.7490/f1000research.1113738.1).
Hoogendoorn, M., Feenstra, T. L., Asukai, Y., Briggs, A. H. , Hansen, R. N., Leidl, R., Risebrough, N., Samyshkin, Y., Wacker, M. and Rutten-van Mölken, M. P.M.H. (2017) External validation of health economic decision models for chronic obstructive pulmonary disease (COPD): report of the third COPD modeling meeting. Value in Health, 20(3), pp. 397-403. (doi: 10.1016/j.jval.2016.10.016) (PMID:28292484)
Bousquet, J. et al. (2017) Erratum to: scaling up strategies of the chronic respiratory disease programme of the European innovation partnership on active and healthy ageing (Action Plan B3: Area 5). Clinical and Translational Allergy, 7, 5. (doi: 10.1186/s13601-016-0135-6) (PMID:28239450) (PMCID:PMC5319069)
Parker, C., Woods, B., Eaton, J., Ma, E., Selby, R., Benson, E., Engstrom, A., Sajosi, P., Briggs, A. and Bonthapally, V. (2017) Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland. Journal of Medical Economics, 20(1), pp. 8-18. (doi: 10.1080/13696998.2016.1219358) (PMID:27472034)
Tabberer, M., Gonzalez-McQuire, S., Muellerova, H., Briggs, A. , Rutten-van Molken, M., Chambers, M. and Lomas, D. A. (2017) Development of a conceptual model of disease progression for use in economic modeling of chronic obstructive pulmonary disease. Medical Decision Making, 37(4), pp. 440-452. (doi: 10.1177/0272989X16662009) (PMID:27486218)
2016
Bousquet, J. et al. (2016) ARIA 2016: care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. Clinical and Translational Allergy, 6, 47. (doi: 10.1186/s13601-016-0137-4) (PMID:28050247) (PMCID:PMC5203711)
Briggs, A. (2016) A view from the bridge: health economic evaluation - a value-based framework? Health Economics, 25(12), pp. 1499-1502. (doi: 10.1002/hec.3448) (PMID:27870333)
Wilkinson, T. et al. (2016) The international decision support initiative reference case for economic evaluation: an aid to thought. Value in Health, 19(8), pp. 921-928. (doi: 10.1016/j.jval.2016.04.015) (PMID:27987641)
Briggs, A. H. , Parfrey, P. S., Khan, N., Tseng, S., Dehmel, B., Kubo, Y., Chertow, G. M. and Belozeroff, V. (2016) Analyzing health-related quality of life in the evolve trial: the joint impact of treatment and clinical events. Medical Decision Making, 36(8), pp. 965-972. (doi: 10.1177/0272989x16638312) (PMID:26987347)
Wildman, J., McMeekin, P., Grieve, E. and Briggs, A. (2016) Economic evaluation of integrated new technologies for health and social care: Suggestions for policy makers, users and evaluators. Social Science and Medicine, 169, pp. 141-148. (doi: 10.1016/j.socscimed.2016.09.033) (PMID:27721138)
Bouttell, J. , Lewsey, J. , Geue, C. , Antony, G., Briggs, A. , McCartney, G., Hutchinson, S., Graham, L. and Heydtmann, M. (2016) The SCottish alcoholic liver disease evaluation: a population-level matched cohort study of hospital-based costs, 1991-2011. PLoS ONE, 11(10), e0162980. (doi: 10.1371/journal.pone.0162980) (PMID:27783619) (PMCID:PMC5082635)
Willett, K. et al. (2016) Close contact casting vs surgery for initial treatment of unstable ankle fractures in older adults: a randomized clinical trial. JAMA: Journal of the American Medical Association, 316(14), pp. 1455-1463. (doi: 10.1001/jama.2016.14719) (PMID:27727383)
Keene, D. J. et al. (2016) The Ankle Injury Management (AIM) trial: a pragmatic, multicentre, equivalence randomised controlled trial and economic evaluation comparing close contact casting with open surgical reduction and internal fixation in the treatment of unstable ankle fractures in patients aged over 60 years. Health Technology Assessment, 20(75), (doi: 10.3310/hta20750) (PMID:27735787)
Städler, N., Shang, A., Bosch, F., Briggs, A. , Goede, V., Berthier, A., Renaudin, C. and Leblond, V. (2016) A systematic review and network meta-analysis to evaluate the comparative efficacy of interventions for unfit patients with chronic lymphocytic leukemia. Advances in Therapy, 33(10), pp. 1814-1830. (doi: 10.1007/s12325-016-0398-2) (PMID:27535291)
Hoogendoorn, M. et al. (2016) Patient heterogeneity in health economic decision models for chronic obstructive pulmonary disease: are current models suitable to evaluate personalized medicine? Value in Health, 19(6), pp. 800-810. (doi: 10.1016/j.jval.2016.04.002) (PMID:27712708)
Wolowacz, S. E., Briggs, A. , Belozeroff, V., Clarke, P., Doward, L., Goeree, R., Lloyd, A. and Norman, R. (2016) Estimating health-state utility for economic models in clinical studies: an ISPOR good research practices task force report. Value in Health, 19(6), pp. 704-719. (doi: 10.1016/j.jval.2016.06.001) (PMID:27712695)
Bousquet, J. et al. (2016) Scaling up strategies of the chronic respiratory disease programme of the European innovation partnership on active and healthy ageing (Action Plan B3: Area 5). Clinical and Translational Allergy, 2016(6), 29. (doi: 10.1186/s13601-016-0116-9) (PMID:27478588) (PMCID:PMC4966705)
Lawson, K., Briggs, A. , Lewsey, J. , Ford, I. , Watt, G., Tunstall-Pedoe, H., Woodward, M., Ritchie, L., Kent, S. and Neilson, M. (2016) A cardiovascular disease policy model: part 2 – preparing for economic evaluation and to assess health inequalities. Open Heart, 3(1), e000140. (doi: 10.1136/openhrt-2014-000140) (PMID:27335653) (PMCID:PMC4908904)
Lee, M. M.Y. et al. (2016) Non-invasive versus invasive management in patients with prior coronary artery bypass surgery with a non-ST segment elevation acute coronary syndrome: study design of the pilot randomised controlled trial and registry (CABG-ACS). Open Heart, 3(1), e000371. (doi: 10.1136/openhrt-2015-000371) (PMID:27110377) (PMCID:PMC4838768)
Boyd, K. A. , Briggs, A. H. , Bauld, L., Sinclair, L. and Tappin, D. (2016) Are financial incentives cost-effective to support smoking cessation during pregnancy? Addiction, 111(2), pp. 360-370. (doi: 10.1111/add.13160) (PMID:26370095)
Briggs, A. and Nugent, R. (2016) Editorial. Health Economics, 25(S1), pp. 6-8. (doi: 10.1002/hec.3321) (PMID:26804358)
Thiele, H. et al. (2016) Multivessel versus culprit lesion only percutaneous revascularization plus potential staged revascularization in patients with acute myocardial infarction complicated by cardiogenic shock: design and rationale of CULPRIT-SHOCK trial. American Heart Journal, 172, pp. 160-169. (doi: 10.1016/j.ahj.2015.11.006) (PMID:26856228)
Becker, U., Briggs, A. H. , Moreno, S. G., Ray, J. A., Ngo, P. and Samanta, K. (2016) Cost-effectiveness model for chemoimmunotherapy options in patients with previously untreated chronic lymphocytic leukemia unsuitable for full-dose fludarabine-based therapy. Value in Health, 19(4), pp. 374-382. (doi: 10.1016/j.jval.2015.12.018) (PMID:27325329)
Gumley, A. et al. (2016) A parallel group randomised open blinded evaluation of Acceptance and Commitment Therapy for Depression After Psychosis: A Pilot Trial Protocol (ADAPT). Psychosis, 8(2), pp. 143-155. (doi: 10.1080/17522439.2015.1100669)
Tremblay, G., Livings, C., Crowe, L., Kapetanakis, V. and Briggs, A. (2016) Determination of the most appropriate method for extrapolating overall survival data from a placebo-controlled clinical trial of lenvatinib for progressive, radioiodine-refractory differentiated thyroid cancer. ClinicoEconomics and Outcomes Research, 2016(8), pp. 323-333. (doi: 10.2147/CEOR.S107498) (PMID:27418847) (PMCID:PMC4934460)
2015
Jahoda, A. , Melville, C. , Cooper, S.-A. , Hastings, R., Briggs, A. , Dagnan, D., Hatton, C., McConnachie, A. , Williams, C. and Jones, R. P. (2015) BEAT-IT: a randomised controlled trial comparing a behavioural activation treatment for depression in adults with intellectual disabilities with an attention control: summary of study protocol. Trials, 16, 595. (doi: 10.1186/s13063-015-1103-5) (PMID:26714891) (PMCID:PMC4696180)
Belozeroff, V., Chertow, G. M., Graham, C. N., Dehmel, B., Parfrey, P. S. and Briggs, A. H. (2015) Economic evaluation of cinacalcet in the United States: the EVOLVE trial. Value in Health, 18(8), pp. 1079-1087. (doi: 10.1016/j.jval.2015.08.007) (PMID:26686794)
Nam, J. et al. (2015) Fractional flow reserve (FFR) versus angiography in guiding management to optimise outcomes in non-ST segment elevation myocardial infarction (FAMOUS-NSTEMI) developmental trial: cost-effectiveness using a mixed trial- and model-based methods. Cost Effectiveness and Resource Allocation, 2015(13), 19. (doi: 10.1186/s12962-015-0045-9) (PMID:26578850) (PMCID:PMC4647286)
McMurray, J.J. et al. (2015) A new cost-effectiveness modelling approach in chronic heart failure with reduced ejection fraction - PCV118. Value in Health, 18(7), A394. (doi: 10.1016/j.jval.2015.09.887) (PMID:26532224)
Bousquet, J. et al. (2015) MACVIA-ARIA sentinel networK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. Allergy, 70(11), pp. 1372-1392. (doi: 10.1111/all.12686) (PMID:26148220)
Reed, S. D. et al. (2015) Tools for economic analysis of patient management interventions in heart failure cost-effectiveness model: a web-based program designed to evaluate the cost-effectiveness of disease management programs in heart failure. American Heart Journal, 170(5), pp. 951-960. (doi: 10.1016/j.ahj.2015.08.015) (PMID:26542504)
Boyd, K. A. , Jones, R. J. , Paul, J. , Birrell, F., Briggs, A. H. and Leung, H. Y. (2015) Decision-analytic cost-effectiveness model to compare prostate cryotherapy to androgen deprivation therapy for treatment of radiation recurrent prostate cancer. BMJ Open, 5(10), e007925. (doi: 10.1136/bmjopen-2015-007925) (PMID:26482768) (PMCID:PMC4611206)
Lorgelly, P. K., Lorimer, K., Fenwick, E. A.L., Briggs, A. H. and Anand, P. (2015) Operationalising the capability approach as an outcome measure in public health: the development of the OCAP-18. Social Science and Medicine, 142, pp. 68-81. (doi: 10.1016/j.socscimed.2015.08.002) (PMID:26291444)
Old, O., Moayyedi, P., Love, S., Roberts, C., Hapeshi, J., Foy, C., Stokes, C., Briggs, A. , Jankowski, J. and Barr, H. (2015) Barrett's oesophagus surveillance versus endoscopy at need study (BOSS): protocol and analysis plan for a multicentre randomized controlled trial. Journal of Medical Screening, 22(3), pp. 158-164. (doi: 10.1177/0969141315575052) (PMID:25767103)
Wolowacz, S., Pearson, I., Shannon, P., Chubb, B., Gundgaard, J., Davies, M. and Briggs, A. (2015) Development and validation of a cost-utility model for Type 1 diabetes mellitus. Diabetic Medicine, 32(8), pp. 1023-1035. (doi: 10.1111/dme.12663) (PMID:25484028)
Devereux, G. et al. (2015) Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial. Trials, 16, 267. (doi: 10.1186/s13063-015-0782-2) (PMID:26058585) (PMCID:PMC4465017)
Govan, L. , Wu, O. , Lindsay, R. and Briggs, A. (2015) How do diabetes models measure up? A review of diabetes economic models and ADA guidelines. Journal of Health Economics and Outcomes Research, 3(2), pp. 132-152.
Husereau, D., Drummond, M., Petrou, S., Greenberg, D., Mauskopf, J., Augustovski, F., Briggs, A. H. , Moher, D., Loder, E. and Carswell, C. (2015) Reply to Roberts et al.: CHEERS is sufficient for reporting cost-benefit analysis, but may require further elaboration. PharmacoEconomics, 33(5), pp. 535-536. (doi: 10.1007/s40273-015-0277-8) (PMID:25893576)
Stollenwerk, B., Lhachimi, S. K., Briggs, A. , Fenwick, E., Caro, J. J., Siebert, U., Danner, M. and Gerber-Grote, A. (2015) Communicating the parameter uncertainty in the IQWiG efficiency frontier to decision-makers. Health Economics, 24(4), pp. 481-490. (doi: 10.1002/hec.3041) (PMID:24590819)
Geue, C. , Lorgelly, P., Lewsey, J. , Hart, C. and Briggs, A. (2015) Hospital expenditure at the end-of-life: what are the impacts of health status and health risks? PLoS ONE, 10(3), e0119035. (doi: 10.1371/journal.pone.0119035) (PMID:25746728) (PMCID:PMC4352086)
Ramsey, S. D., Willke, R. J., Glick, H., Reed, S. D., Augustovski, F., Jonsson, B., Briggs, A. and Sullivan, S. D. (2015) Cost-effectiveness analysis alongside clinical trials II—An ISPOR Good Research Practices Task Force Report. Value in Health, 18(2), pp. 161-172. (doi: 10.1016/j.jval.2015.02.001) (PMID:25773551)
Layland, J. et al. (2015) Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-ST-segment elevation myocardial infarction: the British Heart Foundation FAMOUS-NSTEMI randomized trial. European Heart Journal, 36(2), pp. 100-111. (doi: 10.1093/eurheartj/ehu338) (PMID:25179764) (PMCID:PMC4291317)
Cook, J. A. et al. (2015) Specifying the target difference in the primary outcome for a randomised controlled trial: guidance for researchers. Trials, 16(1), 12. (doi: 10.1186/s13063-014-0526-8) (PMID:25928502) (PMCID:PMC4302137)
Haines, P., Tremblay, G. and Briggs, A. (2015) A criterion-based approach for the systematic and transparent extrapolation of clinical trial survival data. Journal of Health Economics and Outcomes Research, 2(2), pp. 147-160.
Lewsey, J. et al. (2015) Temporal trends and risk factors for readmission for infections, gastrointestinal and immobility complications after an incident hospitalisation for stroke in Scotland between 1997 and 2005. BMC Neurology, 15(3), (doi: 10.1186/s12883-014-0257-1) (PMID:25591718) (PMCID:PMC4320501)
Logue, J. et al. (2015) SurgiCal Obesity Treatment Study (SCOTS): protocol for a national prospective cohort study of patients undergoing bariatric surgery in Scotland. BMJ Open, 5(5), e008106. (doi: 10.1136/bmjopen-2015-008106) (PMID:26002692) (PMCID:PMC4442215)
2014
Welsh, P. et al. (2014) Contrasting associations of insulin resistance with diabetes, cardiovascular disease and all-cause mortality in the elderly: PROSPER long-term follow-up. Diabetologia, 57(12), pp. 2513-2520. (doi: 10.1007/s00125-014-3383-9) (PMID:25264116)
Geue, C. , Briggs, A. , Lewsey, J. and Lorgelly, P. (2014) Population ageing and healthcare expenditure projections: new evidence from a time to death approach. European Journal of Health Economics, 15(5), pp. 885-896. (doi: 10.1007/s10198-013-0543-7)
Boyd, K.A. , Briggs, A.H. , Bauld, L., Sinclair, L. and Tappin, D. (2014) Are financial incentives cost-effective for smoking cessation amongst pregnant women? European Journal of Public Health, 24(S2), p. 146. (doi: 10.1093/eurpub/cku162.090)
Bousquet, J. et al. (2014) Integrated care pathways for airway diseases (AIRWAYS-ICPs). European Respiratory Journal, 44(2), pp. 304-323. (doi: 10.1183/09031936.00014614)
Hoogendoorn, M. et al. (2014) Cost-effectiveness models for chronic obstructive pulmonary disease: cross-model comparison of hypothetical treatment scenarios. Value in Health, 17(5), pp. 525-536. (doi: 10.1016/j.jval.2014.03.1721)
Cook, J. A., Hislop, J. M., Altman, D. G., Briggs, A. H. , Fayers, P. M., Norrie, J. D., Ramsay, C. R., Harvey, I. M. and Vale, L. D. (2014) Use of methods for specifying the target difference in randomised controlled trial sample size calculations: Two surveys of trialists' practice. Clinical Trials, 11(3), pp. 300-308. (doi: 10.1177/1740774514521907) (PMID:24603006)
Boyd, K.A. , Jones, R.J. , Paul, J. , Briggs, A. and Leung, H.Y. (2014) A decision-analytic cost-effectiveness model to compare treatment options for radiation recurrent prostate cancer against androgen deprivation therapy. British Journal of Surgery, 101(s4), p. 59. (doi: 10.1002/bjs.9510)
Cooke, J. A. et al. (2014) Assessing methods to specify the target difference for a randomised controlled trial: DELTA (Difference ELicitation in TriAls) review. Health Technology Assessment, 18(28), v-vi, 1. (doi: 10.3310/hta18280)
Levy, A. R., Briggs, A. H. , Johnston, K., MacLean, J. R., Yuan, Y., L’Italien, G. J., Kalsekar, A. and Schnitzler, M. A. (2014) Projecting long-term graft and patient survival after transplantation. Value in Health, 17(2), pp. 254-260. (doi: 10.1016/j.jval.2014.01.001)
Caro, J.J., Eddy, D. M., Kan, H., Kaltz, C., Patel, B., Eldessouki, R. and Briggs, A. H. (2014) Questionnaire to assess relevance and credibility of modeling studies for informing health care decision making: an ISPOR-AMCP-NPC good practice task force report. Value in Health, 17(2), pp. 174-182. (doi: 10.1016/j.jval.2014.01.003)
Looker, H.C. et al. (2014) Risk stratification for diabetic eye screening: reply to Stratton I. M. and Aldington S. J. Diabetologia, 57(1), pp. 260-261. (doi: 10.1007/s00125-013-3099-2)
Samyshkin, Y., Kotchie, R. W., Mörk, A.-C., Briggs, A. H. and Bateman, E. D. (2014) Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom. European Journal of Health Economics, 15(1), pp. 69-82. (doi: 10.1007/s10198-013-0456-5) (PMID:23392624) (PMCID:PMC3889819)
Briggs, A. (2014) Statistical issues in economic evaluations. In: Culyer, A. J. (ed.) Encyclopedia of Health Economics. Elsevier, pp. 352-361. ISBN 9780123756787 (doi: 10.1016/B978-0-12-375678-7.01418-8)
Campbell, J. D., McQueen, R. B. and Briggs, A. (2014) The “E” in cost-effectiveness analyses. A case study of omalizumab efficacy and effectiveness for cost-effectiveness analysis evidence. Annals of the American Thoracic Society, 11(Sup 2), S105-S111. (doi: 10.1513/AnnalsATS.201309-295RM)
Dundas, R. , Ouédraogo, S., Bond, L., Briggs, A.H. , Chalmers, J., Gray, R., Wood, R. and Leyland, A.H. (2014) Evaluation of Health in Pregnancy grants in Scotland: a protocol for a natural experiment. BMJ Open, 4(10), e006547. (doi: 10.1136/bmjopen-2014-006547)
Hislop, J. et al. (2014) Methods for specifying the target difference in a randomised controlled trial: the Difference ELicitation in TriAls (DELTA) Systematic Review. PLoS Medicine, 11(5), e1001645. (doi: 10.1371/journal.pmed.1001645)
Lewsey, J.D. et al. (2014) A cardiovascular disease policy model that predicts life expectancy taking into account socioeconomic deprivation. Heart, 101(3), pp. 201-208. (doi: 10.1136/heartjnl-2014-305637)
Munge, K. and Briggs, A. H. (2014) The progressivity of health-care financing in Kenya. Health Policy and Planning, 29(7), pp. 912-920. (doi: 10.1093/heapol/czt073)
Willett, K. et al. (2014) Ankle Injury Management (AIM): design of a pragmatic multi-centre equivalence randomised controlled trial comparing close contact casting (CCC) to open surgical reduction and internal fixation (ORIF) in the treatment of unstable ankle fractures in patients over 60 years. BMC Musculoskeletal Disorders, 15, 79. (doi: 10.1186/1471-2474-15-79) (PMID:24621174) (PMCID:PMC4234276)
2013
Layland, J. et al. (2013) TCT-84 Fractional Flow Reserve versus Angiography in Guiding Management to Optimize Outcomes in Non-ST Elevation Myocardial Infarction (FAMOUS - NSTEMI) Clinical Trial: Study Design and Baseline Characteristics of Randomized Participants. Journal of the American College of Cardiology, 62(18), B27. (doi: 10.1016/j.jacc.2013.08.1636)
Berry, C. et al. (2013) Fractional flow reserve versus angiography in guiding management to optimize outcomes in non–ST-elevation myocardial infarction (FAMOUS-NSTEMI): rationale and design of a randomized controlled clinical trial. American Heart Journal, 166(4), 662-668.e3. (doi: 10.1016/j.ahj.2013.07.011)
Jaime Caro, J., Eddy, D.M., Hollingworth, W., Tsevat, J., McDonald, K.M., Wong, J.B., Briggs, A.H. , Siebert, U. and Kuntz, K.M. (2013) ISPOR-SMDM task force’s recommendations for good modeling practices—reply to letter to the editor by Corro Ramos. Value in Health, 16(6), p. 1108. (doi: 10.1016/j.jval.2013.06.016)
Looker, H.C. et al. (2013) Predicted impact of extending the screening interval for diabetic retinopathy: the Scottish Diabetic Retinopathy Screening programme. Diabetologia, 56(8), pp. 1716-1725. (doi: 10.1007/s00125-013-2928-7)
Roberts, N.J., Lewsey, J.D. , Gillies, M., Briggs, A.H. , Belozeroff, V., Globe, D.R., Chiou, C.-F., Lin, S.-L. and Globe, G. (2013) Time trends in 30 day case-fatality following hospitalisation for asthma in adults in Scotland: a retrospective cohort study from 1981-2009. Respiratory Medicine, 107(8), pp. 1172-1177. (doi: 10.1016/j.rmed.2013.04.004)
Tigbe, W.W., Briggs, A.H. and Lean, M.E.J. (2013) A patient-centred approach to estimate total annual healthcare cost by body mass index in the UK Counterweight programme. International Journal of Obesity, 37(8), pp. 1135-1139. (doi: 10.1038/ijo.2012.186)
Garrison, L.P., Towse, A., Briggs, A. , de Pouvourville, G., Grueger, J., Mohr, P.E., Severens, J.L., Siviero, P. and Sleeper, M. (2013) Performance-based risk-sharing arrangements—good practices for design, implementation, and evaluation: report of the ispor good practices for performance-based risk-sharing arrangements task force. Value in Health, 16(5), pp. 703-719. (doi: 10.1016/j.jval.2013.04.011)
Hemingway, H. et al. (2013) Prognosis research strategy (PROGRESS) 1: a framework for researching clinical outcomes. British Medical Journal, 2013(346), e5595. (doi: 10.1136/bmj.e5595)
Riley, R. D. et al. (2013) Prognosis Research Strategy (PROGRESS) 2: prognostic factor research. PLoS Medicine, 10(2), e1001380. (doi: 10.1371/journal.pmed.1001380)
Murphy, A., Fenwick, E., Toff, W.D., Neilson, M.P., Berry, C. , Uren, N., Oldroyd, K.G. and Briggs, A.H. (2013) Transcatheter aortic valve implantation for severe aortic stenosis: the cost-effectiveness case for inoperable patients in the United Kingdom. International Journal of Technology Assessment in Health Care, 29(01), pp. 12-19. (doi: 10.1017/S0266462312000670)
Boyd, K. and Briggs, A. (2013) Statistical issues with trial data and economic modeling for cost-effectiveness evaluation. In: Tang, W. and Tu, X. (eds.) Modern Clinical Trial Analysis. Series: Applied bioinformatics and biostatistics in cancer research. Springer-Verlag: New York, NY, USA, pp. 149-166. ISBN 9781461443216 (doi: 10.1007/978-1-4614-4322-3_6)
Davies, C., Briggs, A. , Lorgelly, P., Garellick, G. and Malchau, H. (2013) The 'hazards' of extrapolating survival curves. Medical Decision Making, 33(3), pp. 369-380. (doi: 10.1177/0272989X12475091) (PMID:23457025)
Grutters, J.P.C., Sculpher, M., Briggs, A.H. , Severens, J.L., Candel, M.J., Stahl, J.E., de Ruysscher, D., Boer, A., Ramaekers, B.L.T. and Joore, M.A. (2013) Acknowledging patient heterogeneity in economic evaluation. PharmacoEconomics, 31(2), pp. 111-123. (doi: 10.1007/s40273-012-0015-4)
Husereau, D., Drummond, M., Petrou, S., Carswell, C., Moher, D., Greenberg, D., Augustovski, F., Briggs, A.H. , Mauskopf, J. and Loder, E. (2013) Consolidated Health Economic Evaluation Reporting Standards (CHEERS) - explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value in Health, 16(2), pp. 231-250. (doi: 10.1016/j.jval.2013.02.002)
Husereau, D., Drummond, M., Petrou, S., Carswell, C., Moher, D., Greenberg, D., Augustovski, F., Briggs, A.H. , Mauskopf, J. and Loder, E. (2013) Consolidated health economic evaluation reporting standards (CHEERS) statement. British Medical Journal, 346(f1049), (doi: 10.1136/bmj.f1049)
Lloyd, S.M. et al. (2013) Long-term effects of statin treatment in elderly people: Extended follow-up of the PROspective study of Pravastatin in the elderly at risk (PROSPER). PLoS ONE, 8(9), e72642. (doi: 10.1371/journal.pone.0072642) (PMID:24023757) (PMCID:PMC3759378)
Silveirinha de Oliveira, E., Aspinall, P., Briggs, A. , Cummins, S., Leyland, A. , Mitchell, R. , Roe, J. and Ward Thompson, C. (2013) How effective is the Forestry Commission Scotland's woodland improvement programme--'Woods In and Around Towns' (WIAT)--at improving psychological well-being in deprived urban communities? A quasi-experimental study. BMJ Open, 3(8), e003648. (doi: 10.1136/bmjopen-2013-003648) (PMID:23996826) (PMCID:PMC3758971)
2012
Geue, C. , Lewsey, J. , Lorgelly, P., Govan, L. , Hart, C. and Briggs, A. (2012) Spoilt for choice: implications of costing hospital episode statistics. Health Economics, 21(10), pp. 1201-1216. (doi: 10.1002/hec.1785)
Briggs, A.H. , Weinstein, M.C., Fenwick, E.A.L., Karnon, J., Sculpher, M.J. and Paltiel, A.D. (2012) Model parameter estimation and uncertainty: a report of the ISPOR-SMDM modeling good research practices task force-6. Value in Health, 15(6), pp. 835-842. (doi: 10.1016/j.jval.2012.04.014)
Caro, J.J., Briggs, A.H. , Siebert, U. and Kuntz, K.M. (2012) modeling good research practices—overview: a report of the ISPOR-SMDM modeling good research practices task force-1. Value in Health, 15(6), pp. 796-803. (doi: 10.1016/j.jval.2012.06.012)
Wu, O. , Briggs, A. and MacIntyre, K. (2012) Mobile phone use for contacting emergency services in life-threatening circumstances. Journal of Emergency Medicine, 42(3), pp. 291-298. (doi: 10.1016/j.jemermed.2011.02.022)
Briggs, A. (2012) The ends justify the mean: outcome measures for estimating the value of new cancer therapies. Health Outcomes Research in Medicine, 3(1), e25-e26. (doi: 10.1016/j.ehrm.2012.01.001)
Briggs, A.H. , Weinstein, M.C., Fenwick, E.A.L., Karnon, J., Sculpher, M.J. and Paltiel, A.D. (2012) Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working group - 6. Medical Decision Making, 32(5), pp. 722-732. (doi: 10.1177/0272989X12458348)
Caro, J.J., Briggs, A.H. , Siebert, U. and Kuntz, K.M. (2012) Modeling good research practices - overview: a report of the ISPOR-SMDM modeling good research practices task force - 1. Medical Decision Making, 32(5), pp. 667-677. (doi: 10.1177/0272989X12454577)
Govan, L. et al. (2012) The effect of deprivation and HbA1c on admission to hospital for diabetic ketoacidosis in type 1 diabetes. Diabetologia, 55(9), pp. 2356-2360. (doi: 10.1007/s00125-012-2601-6)
Roberts, N.J., Boyd, K. , Briggs, A.H. , Caress, A.L. and Partridge, M.R. (2012) Nurse led versus lay educators support for those with asthma in primary care: a costing study. BMC Pulmonary Medicine, 12(52), (doi: 10.1186/1471-2466-12-52)
Tappin, D.M. et al. (2012) The cessation in pregnancy incentives trial (CPIT): study protocol for a randomized controlled trial. Trials, 13(113), (doi: 10.1186/1745-6215-13-113) (PMID:22818493) (PMCID:PMC3482147)
2011
McLean, R.C., Briggs, A.H. , Slack, R., Zamvar, V., Berg, G.A., El-Shafei, H., Oldroyd, K.G. and Pell, J.P. (2011) Perioperative and long-term outcomes following aortic valve replacement: a population cohort study of 4124 consecutive patients. European Journal of Cardio-Thoracic Surgery, 40(6), pp. 1508-1514. (doi: 10.1016/j.ejcts.2011.01.088)
Boyd, K.A. , Briggs, A.H. , Fenwick, E., Norrie, J. and Stock, S. (2011) Power and sample size for cost-effectiveness analysis: fFN neonatal screening. Contemporary Clinical Trials, 32(6), pp. 893-901. (doi: 10.1016/j.cct.2011.07.007)
Govan, L. et al. (2011) Achieved levels of HbA1c and likelihood of hospital admission in people with type 1 diabetes in the Scottish population: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetes Care, 34(9), pp. 1992-1997. (doi: 10.2337/dc10-2099)
Macpherson, K.J. et al. (2011) Trends in incidence and in short term survival following a subarachnoid haemorrhage in Scotland, 1986 - 2005: a retrospective cohort study. BMC Neurology, 11(1), p. 38. (doi: 10.1186/1471-2377-11-38)
Price, M.J., Welton, N.J., Briggs, A.H. and Ades, A.E. (2011) Model averaging in the presence of structural uncertainty about treatment effects: influence on treatment decision and expected value of information. Value in Health, 14(2), pp. 205-218. (doi: 10.1016/j.jval.2010.08.001)
Starkie, H.J., Briggs, A.H. , Chambers, M.G. and Jones, P. (2011) Predicting EQ-5D Values Using the SGRQ. Value in Health, 14(2), pp. 354-360. (doi: 10.1016/j.jval.2010.09.011)
Bauld, L., Boyd, K. A. , Briggs, A. H. , Chesterman, J., Ferguson, J., Judge, K. and Hiscock, R. (2011) One-year outcomes and a cost-effectiveness analysis for smokers accessing group-based and pharmacy-led cessation services. Nicotine and Tobacco Research, 13(2), pp. 135-145. (doi: 10.1093/ntr/ntq222)
Barton, P., Andronis, L., Briggs, A. , McPherson, K. and Capewell, S. (2011) Effectiveness and cost effectiveness of cardiovascular disease prevention in whole populations: modelling study. British Medical Journal, 343, d4044. (doi: 10.1136/bmj.d4044)
Bousquet, J. et al. (2011) How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA2LEN statement. Allergy, 66(6), pp. 765-774. (doi: 10.1111/j.1398-9995.2011.02590.x)
Boyd, K.A. , Briggs, A. , Paul, J. , Iveson, T., Midgely, R., Harkin, A., Bates, G., Alexander, L. and Cassidy, J. (2011) Analysis of adverse events and quality of life data for an economic evaluation of adjuvant chemotherapy in colorectal cancer: when can we stop collecting? Trials, 12, A41. (doi: 10.1186/1745-6215-12-S1-A41)
Cummins, E., Asseburg, C., Punekar, Y.S., Shore, E., Morris, J., Briggs, A. and Fenwick, E.L. (2011) Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis. Value in Health, 14(1), pp. 15-23. (doi: 10.1016/j.jval.2010.10.016)
Govan, L. et al. (2011) Inpatient costs for people with type 1 and type 2 diabetes in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia, 54(8), pp. 2000-2008. (doi: 10.1007/s00125-011-2176-7)
2010
Boyd, K.A. , Fenwick, E. and Briggs, A. (2010) Using an iterative approach to economic evaluation in the drug development process. Drug Development Research, 71(8), pp. 470-477. (doi: 10.1002/ddr.20421)
Mihaylova, B., Briggs, A. , O'Hagan, A. and Thompson, S.G. (2010) Review of statistical methods for analysing healthcare resources and costs. Health Economics, 20(8), pp. 897-916. (doi: 10.1002/hec.1653)
Lorgelly, P.K., Lawson, K.D., Fenwick, E.A.L. and Briggs, A.H. (2010) Outcome Measurement in Economic Evaluations of Public Health Interventions: a Role for the Capability Approach? International Journal of Environmental Research and Public Health, 7(5), pp. 2274-2289. (doi: 10.3390/ijerph7052274) (PMID:20623024) (PMCID:PMC2898049)
Briggs, A.H., Glick, H.A., Lozano-Ortega, G., Spencer, M., Calverley, P.M.A., Jones, P.W. and Vestbo, J. (2010) Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal, 35(3), pp. 532-539. (doi: 10.1183/09031936.00153108)
Briggs, A. , Ritchie, K., Fenwick, E., Chalkidou, K. and Littlejohns, P. (2010) Access with evidence development in the UK past experience, current initiatives and future potential. PharmacoEconomics, 28(2), pp. 163-170. (doi: 10.2165/11531410-000000000-00000)
Lorgelly, P.K. et al. (2010) An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial. European Journal of Heart Failure, 12(1), pp. 66-74. (doi: 10.1093/eurjhf/hfp172)
Briggs, A.H. (2010) Transportability of comparative effectiveness and cost-effectiveness between countries. Value in Health, 13, S22-S25. (doi: 10.1111/j.1524-4733.2010.00751.x)
Campbell, H.E., Gray, A.M., Harris, A.L., Briggs, A.H. and Taylor, M.A. (2010) Estimation and external validation of a new prognostic model for predicting recurrence-free survival for early breast cancer patients in the UK. British Journal of Cancer, 103(6), pp. 776-786. (doi: 10.1038/sj.bjc.6605863)
Crott, R. and Briggs, A. (2010) Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences. European Journal of Health Economics, 11(4), pp. 427-434. (doi: 10.1007/s10198-010-0233-7)
Dolan, G.P., Stone, D.H. and Briggs, A. (2010) A systematic review of continuous performance task research in children prenatally exposed to alcohol. Alcohol and Alcoholism, 45(1), pp. 30-38. (doi: 10.1093/alcalc/agp062)
Hollingworth, W., Campbell, J.D., Kowalski, J., Ravelo, A., Girod, I., Briggs, A. and Sullivan, S.D. (2010) Exploring the impact of changes in neurogenic urinary incontinence frequency and condition-specific quality of life on preference-based outcomes. Quality of Life Research, 19(3), pp. 323-331. (doi: 10.1007/s11136-010-9590-z)
Johnston, K.M., Levy, A.R., Lima, V.D., Hogg, R.S., Tyndall, M.W., Gustafson, P., Briggs, A.H. and Montaner, J.S. (2010) Expanding access to HAART: a cost-effective approach for treating and preventing HIV. AIDS, 24(12), pp. 1929-1935. (doi: 10.1097/QAD.0b013e32833af85d)
Langhorne, P. et al. (2010) Estimating the impact of stroke unit care in a whole population: an epidemiological study using routine data. Journal of Neurology, Neurosurgery and Psychiatry, 81(2), pp. 1301-1305. (doi: 10.1136/jnnp.2009.195131)
Lewsey, J. et al. (2010) Temporal trends in hospitalisation for stroke recurrence following incident hospitalisation for stroke in Scotland. BMC Medicine, 8, p. 23. (doi: 10.1186/1741-7015-8-23)
2009
Levy, A., Harrigan, B., Johnston, K. and Briggs, A. (2009) Comparative effectiveness research through the looking glass. Medical Decision Making, 29(6), NP6-NP8. (doi: 10.1177/0272989X09351590)
Lewsey, J. et al. (2009) Age- and sex-specific trends in fatal incidence and hospitalized incidence of stroke in Scotland, 1986 to 2005. Circulation: Cardiovascular Quality and Outcomes, 2(5), pp. 475-483. (doi: 10.1161/CIRCOUTCOMES.108.825968)
Jacobs-van der Bruggen, M. A. M., van Baal, P. H., Hoogenveen, R. T., Feenstra, T. L., Briggs, A. H. , Lawson, K., Feskens, E. J. M. and Baan, C. A. (2009) Cost-effectiveness of lifestyle modification in diabetes patients. Diabetes Care, 32(8), pp. 1453-1458. (doi: 10.2337/dc09-0363)
Wu, O., Levy, A.R., Briggs, A., Lewis, G. and Jardine, A. (2009) Acute rejection and chronic nephropathy: a systematic review of the literature. Transplantation, 87(9), pp. 1330-1339. (doi: 10.1097/TP.0b013e3181a236e0)
Lewsey, J.D. et al. (2009) Sex differences in incidence, mortality, and survival in individuals with stroke in Scotland, 1986 to 2005. Stroke, 40(4), pp. 1038-1043. (doi: 10.1161/STROKEAHA.108.542787)
Mihaylova, B., Briggs, A., Hlatky, M., Armitage, J., Parish, S., Gray, A. and Collins, R. (2009) Statin cost-effectiveness in the United States for people at different vascular risk levels. Circulation: Cardiovascular Quality and Outcomes, 2(2), pp. 65-72. (doi: 10.1161/CIRCOUTCOMES.108.808469)
Boyd, K.A. and Briggs, A.H. (2009) Cost-effectiveness of pharmacy and group behavioural support smoking cessation services in Glasgow. Addiction, 104(2), pp. 317-325. (doi: 10.1111/j.1360-0443.2008.02449.x)
Briggs, A. , Starkie, H. and Wu, O. (2009) Health economics in asthma and COPD. In: Barnes, P.J., Drazen, J.M., Rennard, S.I. and Thomson, N.C. (eds.) Asthma and COPD. Academic Press/Elsevier: London, pp. 751-760. ISBN 9780123740014
Levy, A.R., Szabo, S., Briggs, A. , Pleil, A., Davie, A., Zlateva, G. and Javitt, J. (2009) Joint assessment of intended and unintended effects of medications: an example using vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration. Journal of Ophthalmology, 2009, 540431. (doi: 10.1155/2009/540431) (PMID:20339464) (PMCID:PMC2836847)
2008
Barton, G.R., Briggs, A.H. and Fenwick, E.A.L. (2008) Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). Value in Health, 11(5), pp. 886-897. (doi: 10.1111/j.1524-4733.2008.00358.x)
Levy, A.R., Kowdley, K., Iloeje, U.H., Tafesse, E., Mukherjee, J., Gish, R., Bzowej, N. and Briggs, A.H. (2008) The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value in Health, 11(3), pp. 527-538. (doi: 10.1111/j.1524-4733.2007.00297.x) (PMID:18179664)
Hirst, A., Dutton, S., Wu, O. , Briggs, A. , Edwards, C. , Waldenmaier, L., Maresh, M., Nicholson, A. and McPherson, K. (2008) A multi-centre retrospective cohort study comparing the efficacy, safety and cost-effectiveness of hysterectomy and uterine artery embolisation for the treatment of symptomatic uterine fibroids: the HOPEFUL study. Health Technology Assessment, 12(5),
Briggs, A.H. , Spencer, M., Wang, H., Mannino, D. and Sin, D.D. (2008) Development and validation of a prognostic index for health outcomes in chronic obstructive pulmonary disease. Archives of Internal Medicine, 168(1), pp. 71-79. (doi: 10.1001/archinternmed.2007.37)
Briggs, A., Wild, D., Lees, M., Reaney, M., Dursun, S., Parry, D. and Mukherjee, J. (2008) Impact of schizophrenia and schizophrenia treatment related adverse events on quality of life: direct utility elicitation. Health and Quality of Life Outcomes, 6(105), pp. 1-9. (doi: 10.1186/1477-7525-6-105)
Claxton, K., Briggs, A.H. , Buxton, M.J., Culyer, A.J., McCabe, C., Walker, S. and Sculpher, M.J. (2008) Value based pricing for NHS drugs: an opportunity not to be missed? British Medical Journal, 336(7638), pp. 251-254. (doi: 10.1136/bmj.39434.500185.25)
Eckerman, S., Briggs, A. and Willan, A.R. (2008) Health technology assessment in the cost-disutility plane. Medical Decision Making, 28(2), pp. 172-181. (doi: 10.1177/0272989X07312474)
Hirst, A., Dutton, S., Wu, O. , Briggs, A. , Edwards, C., Waldenmaier, L., Maresh, M., Nicholson, A. and McPherson, K. (2008) The HOPEFUL Study: a multi-centre retrospective cohort study comparing the efficacy, safety and cost-effectiveness of hysterectomy and uterine artery embolisation (UAE) for the treatment of symptomatic uterine fibroids. Health Technology Assessment, 123(5), pp. 1-248.
Starkie, H., Briggs, A.H. and Chamber, M.G. (2008) Pharmacoeconomics in COPD: lessons for the future. International Journal of COPD, 3(1), pp. 71-88.
2007
Campbell, H., Briggs, A.H. , Buxton, M., Kim, L. and Thompson, S. (2007) The credibility of health economic models for health policy decision-making: the case of population screening for abdominal aortic aneurysm. Journal of Health Services Research and Policy, 12(1), pp. 11-17. (doi: 10.1258/135581907779497594)
Briggs, A. et al. (2007) Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. Heart, 93(9), pp. 1081-1086.
Culyer, A., McCabe, C., Briggs, A.H. , Claxton, K., Buxton, M., Akehurst, R., Sculpher, M.J. and Brazier, J. (2007) Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence. Journal of Health Services Research and Policy, 12(1), pp. 56-58.
Kim, L., Thompson, S., Briggs, A. , Buxton, M. and Campbell, H. (2007) How cost-effective is screening for abdominal aortic aneurysms? Journal of Medical Screening, 14(1), pp. 46-52.
Luc, G., Ades, A., Sutton, A., Cooper, N., BriggS, A. and Caldwell, D. (2007) Meta-analysis of mixed treatment comparisons at multiple follow-up times. Statistics in Medicine, 26, pp. 3681-3699. (doi: 10.1002/sim.2831)
Ossa, D.F., Briggs, A.H. , McIntosh, E. , Cowell, W., Littlewood, T. and Sculpher, M.J. (2007) Recombinant erythropoietin for chemotherapy-related anaemia: economic value and health-related quality-of-life assessment using direct utility elicitation and discrete choice experiment methods. PharmacoEconomics, 25(3), pp. 223-237.
2006
Mihaylova, B., Briggs, A.H. , Armitage, J., Parish, S., Gray, A. and Collins, R. (2006) Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people. British Medical Journal, 333(7579), p. 1145. (doi: 10.1136/bmj.38993.731725.BE)
Paul, J. , Briggs, A. , Harking, A., Hayclon, M., Iveson, T., Masterson, M., Midgley, A. and Cassidy, J. (2006) SCOT: short course oncology therapy — a comparison of 12 and 24 weeks of adjuvant chemotherapy in colorectal cancer. In: 2011 ASCO Annual Meeting, Chicago, Ill, USA, 3-7 Jun 2011, e14145.
Briggs, A.H. , Bousquet, J., Wallace, M., Busse, W.W., Clark, T.J.H., Pedersen, S.E. and Baternan, E.D. (2006) Cost-effectiveness of asthma control: an economic appraisal of the GOAL study. Allergy, 61(5), pp. 531-536. (doi: 10.1111/j.1398-9995.2006.01038.x)
Briggs, A.H. and Levy, A.R. (2006) Pharmacoeconomics and pharmacoepidemiology - Curious bedfellows or a match made in heaven? PharmacoEconomics, 24, pp. 1079-1086.
Briggs, A.H. , Lozano-Ortega, G., Spencer, S., Bale, G., Spencer, M.D. and Burge, S. (2006) Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value in Health, 9(4), pp. 227-235. (doi: 10.1111/j.1524-4733.2006.00106.x)
Deckers, J., Goedhart, D., Boersma, E., Briggs, A. , Bertrand, M., Ferrari, R., Remme, W., Fox, K. and imoons, M. (2006) Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk. European Heart Journal, 27, pp. 796-801. (doi: 10.1093/eurheartj/ehi809)
Williams, C. et al. (2006) Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy. Health Technology Assessment, 10, 1-+.
2005
Manca, A., Rice, N., Sculpher, M.J. and Briggs, A.H. (2005) Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models. Health Economics, 14(5), pp. 471-485. (doi: 10.1002/hec.914)
Claxton, K., Sculpher, M., McCabe, C., Briggs, A.H. , Akehurst, R., Buxton, M., Brazier, J. and O'Hagan, T. (2005) Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Economics, 14(4), pp. 339-347. (doi: 10.1002/hec.985)
Briggs, A.H. (2005) Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. Value in Health, 8(1), pp. 1-2. (doi: 10.1111/j.1524-4733.2005.08101.x)
Briggs, A.H. , Nixon, R., Dixon, S. and Thompson, S. (2005) Parametric modelling of cost data: some simulation evidence. Health Economics, 14(4), pp. 421-428. (doi: 10.1002/hec.941)
Briggs, A. (2005) Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. Value in Health, 8(1), pp. 1-2.
Clarke, P., Gray, A., Briggs, A. , Stevens, R., Matthews, D. and Holman, R. (2005) Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia, 48(5), pp. 868-877.
Gagnon, Y., Levy, A., Spencer, M., Hurley, J., Frost, F., Mapel, D. and Briggs, A. (2005) Economic evaluation of treating chronic obstructive pulmonary disease with inhaled corticosteroids and long-acting beta2-agonists in a health maintenance organization. Respiratory Medicine, 99(12), pp. 1534-1545.
Manca, A., Rice, N., Sculpher, M. and Briggs, A. (2005) Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models.[erratum appears in Health Econ. Health Economics, 14(5), pp. 471-485.
Mihaylova, B., Briggs, A. , Armitage, J., Parish, S., Gary, A. and Collins, R. (2005) Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals. Lancet, 365(9473), pp. 1779-1785.
O'Hagan, T. et al. (2005) Incorporation of uncertainty in health economic modelling studies. PharmacoEconomics, 23(6), pp. 529-536.
Ramsey, S. et al. (2005) Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value in Health, 8(5), pp. 521-533.
Reed, S. et al. (2005) Conducting economic evaluations alongside multinational clinical trials: toward a research consensus. American Heart Journal, 149(3), pp. 434-443.
Spencer, M.D., Briggs, A.H. , Grossman, R.J. and Rance, L. (2005) Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. PharmacoEconomics, 23(6), pp. 619-637.
2004
Clarke, P.M., Gray, A.M., Briggs, A. , Farmer, A.J., Fenn, P.,, Stevenson, R.J., Matthews, D.R., Stratton, I.M. and Holman, R.R. (2004) A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia, 47(10), pp. 1747-1759. (doi: 10.1007/s00125-004-1527-z)
Briggs, A.H. (2004) Statistical approaches to handling uncertainty in health economic evaluation. Psychiatrist, 16(6), pp. 551-561.
Briggs, A. (2004) Statistical approaches to handling uncertainty in health economic evaluation. [29 refs]. European Journal of Gastroenterology and Hepatology, 16(6), pp. 551-561.
Briggs, A. , Sculpher, M., Dawson, J. , Fitzpatrick, R., Murray, D. and Malchau, H. (2004) The Use of Probabilistic Decision Models in Technology Assessment: The Case of Total Hip Replacement. Applied Health Economics and Health Policy, 3(2), pp. 78-79.
Clarke, P., Gray, A., Briggs, A., Farmer, A., Fenn, P., Stevens, R., Matthews, D., Stratton, I. and Holman, R. (2004) A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia, 47, pp. 1747-1759. (doi: 10.1007/s00125-004-1527-z)
Gagnon, Y., Levy, A., Iloeje, U. and Briggs, A. (2004) Treatment costs in Canada of health conditions resulting from chronic Hepatitis B infection. Journal of Clinical Gastroenterology, 38(Suppl), S179-S186.
Willan, A., Briggs, A. and Hoch, J. (2004) Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. Health Economics, 13(5), pp. 461-475.
2003
Clarke, P., Gray, A., Legood, R., Briggs, A. and Holman, R. (2003) The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabetic Medicine, 20(6), pp. 442-450. (doi: 10.1046/j.1464-5491.2003.00972.x)
Reed, S.D., Dillingham, P.W., Briggs, A.H. , Veestra, D.L. and Sullivan, S.D. (2003) A Bayesian approach to aid in formulary decision making: incorporating institution-specific cost-effectiveness data with clinical trial results. Medical Decision Making, 23(3), pp. 252-264. (doi: 10.1177/0272989X03023003007)
Briggs, A. , Ades, A. and Price, M. (2003) Probabilistic sensitivity analysis for decision trees with multiple branches: use of the Dirichlet distribution in a Bayesian framework. Medical Decision Making, 23(4), pp. 341-350.
Briggs, A. , Clark, T., Wolstenholme, J. and Clark, P. (2003) Missing ... presumed at random: cost analysis of incomplete data. Health Economics, 12(5), pp. 377-393.
Craig, D. et al. (2003) New BMJ policy on economic evaluations. Economic evaluations should be judged on economic merit. British Medical Journal, 326(7386), p. 445.
Hoch, J., Briggs, A. and Willan, A. (2003) Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Economics, 11(5), pp. 415-430.
Hope, A. and Briggs, A. (2003) Concerns regarding the ISPOR Code of Ethics for Researchers. Value in Health, 7(4), pp. 510-511.
Tytgat, G., Heading, R., Muller-Lissner, S., Kamm, M., Scholmerich, J., Berstad, A., Fried, M., Chaussade, S., Jewell, D. and Briggs, A. (2003) Contemporary understanding and management of reflux and constipation in the general population and pregnancy: a consensus meeting. Alimentary Pharmacology and Therapeutics, 18(3), pp. 291-301. (doi: 10.1046/j.1365-2036.2003.01679.x)
2002
Briggs, A. , Clark, T., Wolstenholme, J. and Clarke, P. (2002) Missing.... presumed at random: cost-analysis of incomplete data. Health Economics, 12(5), pp. 377-392. (doi: 10.1002/hec.766)
O'Brien, B.J. and Briggs, A.H. (2002) Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods. Statistical Methods in Medical Research, 11(6), pp. 455-468. (doi: 10.1191/0962280202sm304ra)
Briggs, A.H. , O'Brien, B.J. and Blackhouse, G. (2002) Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annual Review of Public Health, 23, pp. 377-401. (doi: 10.1146/annurev.publhealth.23.100901.140534)
Blackhouse, G., Briggs, A. and O'Brien, B.J. (2002) A note on the estimation of confidence intervals for cost-effectiveness when costs and effects are censored. Medical Decision Making, 22(2), pp. 173-177. (doi: 10.1177/02729890222063053)
Blackhouse, G., Briggs, A. and O'Brien, B. (2002) Estimation of confidence intervals for cost-effectiveness when costs and effects are censored. Medical Decision Making, 22, pp. 170-174.
Blackhouse, G., Briggs, A. and O'Brien, B. (2002) A note on the estimation of confidence intervals for cost-effectiveness when costs and effects are censored. Medical Decision Making, 22(2), pp. 173-177.
Briggs, A.H. , Goeree, R., Blackhouse, G. and O'Brien, B.J. (2002) Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Medical Decision Making, 22(4), pp. 290-308. (doi: 10.1177/027298902400448867)
Briggs, A. , Goeree, R. and O'Brien, B. (2002) Probabilistic analysis of models: choosing between treatment strategies for gastroesophageal reflux disease. Medical Decision Making, 22(4), pp. 290-308.
Briggs, A. , O'Brien, B. and Blackhouse, G. (2002) Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annual Review of Public Health, 23, pp. 377-401.
Goeree, R., O'Brien, B., Blackhouse, G., Marshall, J., Briggs, A. and Lad, R. (2002) Cost-effectiveness and cost-utility of long-term management strategies for heartburn. Value in Health, 5(4), pp. 312-328.
O'Brien, B. and Briggs, A. (2002) Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods. Statistical Methods in Medical Research, 11(6), pp. 455-468.
Price, M.J. and Briggs, A.H. (2002) Development of an economic model to assess the cost effectiveness of asthma management strategies. PharmacoEconomics, 20(3), pp. 183-194.
2001
Sendi, P.P. and Briggs, A.H. (2001) Affordability and cost-effectiveness: decision-making on the cost-effectiveness plane. Health Economics, 10(7), pp. 675-680. (doi: 10.1002/hec.639)
Briggs, A.H. and O'Brien, B.J. (2001) The death of cost-minimization analysis? Health Economics, 10(2), pp. 179-184. (doi: 10.1002/hec.584)
Briggs, A. (2001) A Bayesian approach to stochastic cost-effectiveness analysis. International Journal of Technology Assessment in Health Care, 17(1), pp. 69-82.
Briggs, A. (2001) A Bayesian approach to stochastic cost-effectiveness analysis. An illustration and application to blood pressure control in type 2 diabetes. International Journal of Technology Assessment in Health Care, 17(1), pp. 69-82.
Briggs, A. and O'Brien, B. (2001) The death of cost-minimization analysis?. [23 refs]. Health Economics, 10(2), pp. 179-184.
Briggs, A. and Tambour, M. (2001) The design and analysis of stochastic cost-effectiveness studies for the evaluation of health care interventions. Drug Information Journal, 35(4), pp. 1455-1468.
Delaney, B.C., Wilson, S.L., Roalfe, A., Briggs, A.H. and Hobbs, F.D.R. (2001) Empirical treatment or prompt endoscopy? - author's reply. Lancet, 357, p. 1366. (doi: 10.1016/S0140-6736(00)04492-5)
Glick, H. and Briggs, A. (2001) Cost-effectiveness of health care interventions: a guide to quantifying stochastic uncertainty and presenting the result of cost-effectiveness analyses. Expert Reviews in Pharmacoeconomics and Outcomes Research, 1(1), pp. 25-36.
Levy, A., Briggs, A. , Demers, C. and O'Brien, B. (2001) Cost-effectiveness of beta-blocker therapy with metoprolol or with carvedilol for treatment of heart failure in Canada. American Heart Journal, 142(3), pp. 537-543.
Articles
Gögenur, M. et al. (2024) Time from colorectal cancer surgery to adjuvant chemotherapy – post hoc analysis of the SCOT trial. JAMA Surgery, 159(8), pp. 865-871. (doi: 10.1001/jamasurg.2024.1555) (PMID:38865139)
Robles-Zurita, J. A., Mcmeekin, N., Sullivan, F., Mair, F. S. and Briggs, A. (2024) Health economic evaluation of lung cancer screening using a diagnostic blood test: the Early detection of Cancer of the Lung Scotland (ECLS). Current Oncology, 31(6), pp. 3546-3562. (doi: 10.3390/curroncol31060261)
Melville, C.A. et al. (2023) Predictors and moderators of the response of adults with intellectual disabilities and depression to behavioural activation and guided self-help therapies. Journal of Intellectual Disability Research, 67(10), pp. 986-1002. (doi: 10.1111/jir.13063) (PMID:37344986)
Breeze, P. R. et al. (2023) Guidance on the use of complex systems models for economic evaluations of public health interventions. Health Economics, 32(7), pp. 1603-1625. (doi: 10.1002/hec.4681) (PMID:37081811)
McEwan, P., Darlington, O., Miller, R., McMurray, J. J.V. , Wheeler, D. C., Heerspink, H. J.L., Briggs, A. , Bergenheim, K. and Garcia Sanchez, J. J. (2022) Cost-effectiveness of dapagliflozin as a treatment for chronic kidney disease: a health-economic analysis of DAPA-CKD. Clinical Journal of the American Society of Nephrology, 17(12), pp. 1730-1741. (doi: 10.2215/CJN.03790322) (PMID:36323444)
Gumley, A. I. et al. (2022) The EMPOWER blended digital intervention for relapse prevention in schizophrenia: a feasibility cluster randomised controlled trial in Scotland and Australia. Lancet Psychiatry, 9(6), pp. 477-486. (doi: 10.1016/S2215-0366(22)00103-1)
Gumley, A. I. et al. (2022) Digital smartphone intervention to recognise and manage early warning signs in schizophrenia to prevent relapse: the EMPOWER feasibility cluster RCT. Health Technology Assessment, 26(27), (doi: 10.3310/hlze0479) (PMID:35639493) (PMCID:PMC9376801)
Kohli-Lynch, C. N., Lewsey, J. , Boyd, K. A. , French, D. D., Jordan, N., Moran, A. E., Sattar, N. , Preiss, D. and Briggs, A. H. (2022) Beyond 10-year risk: a cost-effectiveness analysis of statins for the primary prevention of cardiovascular disease. Circulation, 145(17), pp. 1312-1323. (doi: 10.1161/CIRCULATIONAHA.121.057631) (PMID:35249370) (PMCID:PMC9022692)
Cotton, S. et al. (2022) Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS). Trials, 23, 307. (doi: 10.1186/s13063-022-06226-8) (PMID:35422024) (PMCID:PMC9009490)
Xin, Y. , Gray, E., Robles-Zurita, J. A., Haghpanahan, H. , Heggie, R., Kohli-Lynch, C., Briggs, A. , McAllister, D. A. , Lawson, K. D. and Lewsey, J. (2022) From spreadsheets to script: experiences from converting a Scottish cardiovascular disease policy model into R. Applied Health Economics and Health Policy, 20(2), pp. 149-158. (doi: 10.1007/s40258-021-00684-y) (PMID:34671930)
Hanna, C. R. et al. (2021) Three versus six months of adjuvant doublet chemotherapy for patients with colorectal cancer: a multi-country cost-effectiveness and budget impact analysis. Clinical Colorectal Cancer, 20(3), pp. 236-244. (doi: 10.1016/j.clcc.2021.04.001) (PMID:33992542)
Dick, K., Schneider, J. E., Briggs, A. , Lecomte, P., Regnier, S. A. and Lean, M. (2021) Mendelian randomization: estimation of inpatient hospital costs attributable to obesity. Health Economics Review, 11, 16. (doi: 10.1186/s13561-021-00314-2) (PMID:33990897) (PMCID:PMC8122556)
Sullivan, F. et al. (2021) Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging. European Respiratory Journal, 57(1), 2000670. (doi: 10.1183/13993003.00670-2020) (PMID:32732334)
Bouttell, J. , Briggs, A. and Hawkins, N. (2021) A toolkit of methods of development-focused health technology assessment. International Journal of Technology Assessment in Health Care, 37(1), e84. (doi: 10.1017/S0266462321000507)
Bouttell, J. , Hawkins, N. and Briggs, A. (2021) The thorny issue of value alignment: how development-focused health technology assessment can help find win–win situations for patients and healthcare systems and commercial investors. International Journal of Technology Assessment in Health Care, 37(1), e57. (doi: 10.1017/S026646232100026X) (PMID:33875040)
Robles-Zurita, J. A., Briggs, A. , Rana, D. , Quayyum, Z., Oldroyd, K. G., Zeymer, U., Desch, S., de Waha-Thiele, S. and Thiele, H. (2020) Economic evaluation of culprit lesion only PCI vs. immediate multivessel PCI in acute myocardial infarction complicated by cardiogenic shock: the CULPRIT-SHOCK trial. European Journal of Health Economics, 21, pp. 1197-1209. (doi: 10.1007/s10198-020-01235-3) (PMID:33029668)
Xin, Y. , Davies, A., Briggs, A. , McCombie, L., Messow, C. M. , Grieve, E. , Leslie, W. S., Taylor, R. and Lean, M. E.J. (2020) Type 2 diabetes remission: 2 year within-trial and lifetime-horizon cost-effectiveness of the Diabetes Remission Clinical Trial (DiRECT)/Counterweight-Plus weight management programme. Diabetologia, 63, pp. 2112-2122. (doi: 10.1007/s00125-020-05224-2) (PMID:32776237) (PMCID:PMC7476973)
Bouttell, J. , Briggs, A. and Hawkins, N. (2020) A different animal? Identifying the features of health technology assessment for developers of medical technologies. International Journal of Technology Assessment in Health Care, 36(4), pp. 285-291. (doi: 10.1017/S0266462320000380)
Hájek, R., Gonzalez-McQuire, S., Szabo, Z., Delforge, M., DeCosta, L., Raab, M. S., Bouwmeester, W., Campioni, M. and Briggs, A. (2020) Novel risk stratification algorithm for estimating the risk of death in patients with relapsed multiple myeloma: External validation in a retrospective chart review. BMJ Open, 10(7), e034209. (doi: 10.1136/bmjopen-2019-034209) (PMID:32665382) (PMCID:PMC7365483)
McMeekin, N., Wu, O. , Germeni, E. and Briggs, A. (2020) How methodological frameworks are being developed: evidence from a scoping review. BMC Medical Research Methodology, 20, 173. (doi: 10.1186/s12874-020-01061-4) (PMID:32605535) (PMCID:PMC7325096)
Briggs, A. , Daniele, B., Dick, K., Evans, T. R. J. , Galle, P. R., Hubner, R. A., Lopez, C., Siebert, U. and Tremblay, G. (2020) Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma. British Journal of Cancer, 122(12), pp. 1754-1759. (doi: 10.1038/s41416-020-0817-7) (PMID:32265508) (PMCID:PMC7283323)
McMeekin, N., Geue, C. , Briggs, A. , Rombach, I., Li, H. K., Bejon, P., McNally, M., Atkins, B. L., Ferguson, J. and Scarborough, M. (2020) Cost-effectiveness of oral versus intravenous antibiotics (OVIVA) in patients with bone and joint infection: evidence from a non-inferiority trial. Wellcome Open Research, 4, 108. (doi: 10.12688/wellcomeopenres.15314.4)
Dick, K., Briggs, A. , Ohsfeldt, R., Sydendal Grand, T. and Buchs, S. (2020) A quality of life mapping function developed from a grass pollen sublingual immunotherapy trial to a tree pollen sublingual immunotherapy trial. Journal of Medical Economics, 23(1), pp. 64-69. (doi: 10.1080/13696998.2019.1649268) (PMID:31352853)
Gumley, A. et al. (2020) Early signs monitoring to prevent relapse in psychosis and promote well-being, engagement, and recovery: protocol for a feasibility cluster randomized controlled trial harnessing mobile phone technology blended with peer support. JMIR Research Protocols, 9(1), e15058. (doi: 10.2196/15058) (PMID:31917372)
Iveson, T. et al. (2019) 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT. Health Technology Assessment, 23(64), (doi: 10.3310/hta23640) (PMID:31852579)
Tremblay, G., Westley, T., Forsythe, A., Pelletier, C. and Briggs, A. (2019) A criterion-based approach to systematic and transparent comparative effectiveness: a case study in psoriatic arthritis. Journal of Comparative Effectiveness Research, 8(15), pp. 1265-1298. (doi: 10.2217/cer-2019-0064) (PMID:31774340)
Xin, Y. , Davies, A., McCombie, L., Briggs, A. , Messow, C.-M. , Grieve, E. , Leslie, W.S., Taylor, R. and Lean, M.E.J. (2019) Type 2 diabetes remission: economic evaluation of the DiRECT/Counterweight‐Plus weight management programme within a primary care randomized controlled trial. Diabetic Medicine, 36(8), pp. 1003-1012. (doi: 10.1111/dme.13981) (PMID:31026353)
Devereux, G. et al. (2019) Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT. Health Technology Assessment, 23(37), pp. 1-146. (doi: 10.3310/hta23370)
Grieve, E. and Briggs, A. (2019) IDSI Reference Case work stream. F1000Research, 8, 803. (doi: 10.7490/f1000research.1116834.1)
Ward Thompson, C. et al. (2019) Enhancing health through access to nature: how effective are interventions in woodlands in deprived urban communities? A quasi-experimental study in Scotland, UK. Sustainability, 11(12), 3317. (doi: 10.3390/su11123317) (PMID:31844557) (PMCID:PMC6914372)
Welsh, P. et al. (2019) Cardiac troponin T and troponin I in the general population: comparing and contrasting their genetic determinants and associations with outcomes. Circulation, 139(24), pp. 2754-2764. (doi: 10.1161/CIRCULATIONAHA.118.038529) (PMID:31014085) (PMCID:PMC6571179)
Xin, Y. , Davies, A., McCombie, L., Briggs, A. , Messow, C.-M. , Grieve, E. , Leslie, W. S., Taylor, R. and Lean, M. E.J. (2019) Within-trial cost and 1-year cost-effectiveness of the DiRECT/Counterweight-Plus weight-management programme to achieve remission of type 2 diabetes. Lancet Diabetes and Endocrinology, 7(3), pp. 169-172. (doi: 10.1016/S2213-8587(18)30346-2) (PMID:30581081)
Li, H.-K. et al. (2019) Oral versus intravenous antibiotics for bone and joint infection. New England Journal of Medicine, 380(5), pp. 425-436. (doi: 10.1056/NEJMoa1710926) (PMID:30699315)
Somers, C., Chimonas, S., McIntosh, E. , Kaltenboeck, A., Briggs, A. and Bach, P. (2019) Using nominal group technique to identify key attributes of oncology treatments for a discrete choice experiment. MDM Policy and Practice, 4(1), (doi: 10.1177/2381468319837925) (PMID:30915400) (PMCID:PMC6429659)
Ward Thompson, C. et al. (2019) Health impacts of environmental and social interventions designed to increase deprived communities' access to urban woodlands: a mixed-methods study. Public Health Research, 7(2), (doi: 10.3310/phr07020)
Robles-Zurita, J. A. et al. (2018) SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer. British Journal of Cancer, 119(11), pp. 1332-1338. (doi: 10.1038/s41416-018-0319-z) (PMID:30420616) (PMCID:PMC6265336)
Welsh, P. et al. (2018) Comparison between high-sensitivity cardiac troponin T and cardiac troponin I in a large general population cohort. Clinical Chemistry, 64(11), pp. 1607-1616. (doi: 10.1373/clinchem.2018.292086) (PMID:30126950)
Devereux, G. et al. (2018) Effect of theophylline as adjunct to inhaled corticosteroids on exacerbations in patients with COPD: a randomized clinical trial. JAMA: Journal of the American Medical Association, 320(15), pp. 1548-1559. (doi: 10.1001/jama.2018.14432) (PMID:30326124) (PMCID:PMC6233797)
Jahoda, A. et al. (2018) Behavioural activation versus guided self-help for depression in adults with learning disabilities: the BeatIt RCT. Health Technology Assessment, 22(53), (doi: 10.3310/hta22530) (PMID:30265239)
Dolph, M., Roy, A., Bhor, M., Hearnden, J., Kwon, C. S., Forsythe, A., Tremblay, G. and Briggs, A. (2018) A decision framework for treating chronic immune thrombocytopenia with thrombopoietin receptor agonists. Journal of Comparative Effectiveness Research, 7(8), (doi: 10.2217/cer-2018-0034) (PMID:29848048)
Annemans, L., Packard, C. J. , Briggs, A. and Ray, K. K. (2018) 'Highest risk-highest benefit' strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies. European Heart Journal, 39(27), pp. 2546-2550. (doi: 10.1093/eurheartj/ehx710) (PMID:29236976) (PMCID:PMC6047410)
Ford, T. J. et al. (2018) Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular Angina (CorMicA) stratified medicine clinical trial. American Heart Journal, 201, pp. 86-94. (doi: 10.1016/j.ahj.2018.03.010) (PMID:29803987) (PMCID:PMC6018570)
Gray, C. M. et al. (2018) Long-term weight loss following a randomised controlled trial of a weight management programme for men delivered through professional football clubs: the Football Fans in Training follow-up study. Public Health Research, 6(9), (doi: 10.3310/phr06090) (PMID:30035935)
Gray, C. M. et al. (2018) Long-term weight loss trajectories following participation in a randomised controlled trial of a weight management programme for men delivered through professional football clubs: A longitudinal cohort study and economic evaluation. International Journal of Behavioral Nutrition and Physical Activity, 15, 60. (doi: 10.1186/s12966-018-0683-3) (PMID:29954449) (PMCID:29954449)
Johnson, M. J., McSkimming, P., McConnachie, A. , Geue, C. , Millerick, Y., Briggs, A. and Hogg, K. (2018) The feasibility of a randomised-controlled trial to compare the cost-effectiveness of palliative cardiology or usual care in people with advanced heart failure: two exploratory prospective cohorts. Palliative Medicine, 32(6), pp. 1133-1141. (doi: 10.1177/0269216318763225) (PMID:29688127) (PMCID:PMC5967038)
McMurray, J. J.V. et al. (2018) Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction. Heart, 104(12), pp. 1006-1013. (doi: 10.1136/heartjnl-2016-310661) (PMID:29269379) (PMCID:PMC5992367)
Shah, D., Driessen, M., Risebrough, N., Baker, T., Naya, I., Briggs, A. and Ismaila, A. S. (2018) Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective. Cost Effectiveness and Resource Allocation, 16, 17. (doi: 10.1186/s12962-018-0101-3) (PMID:29773969) (PMCID:PMC5946544)
Stollenwerk, B., Iannazzo, S., Akehurst, R., Adena, M., Briggs, A. , Dehmel, B., Parfrey, P. and Belozeroff, V. (2018) A decision-analytic model to assess the cost-effectiveness of etelcalcetide vs. cinacalcet. PharmacoEconomics, 36(5), pp. 603-612. (doi: 10.1007/s40273-017-0605-2) (PMID:29392552)
Iveson, T. J. et al. (2018) 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. Lancet Oncology, 19(4), pp. 562-578. (doi: 10.1016/S1470-2045(18)30093-7) (PMID:29611518) (PMCID:PMC5883334)
Brazier, J., Briggs, A. and Bryan, S. (2018) EQ-5D-5L: Smaller steps but a major step change? Health Economics, 27(1), pp. 4-6. (doi: 10.1002/hec.3627) (PMID:29411469)
Morton, A., Bach, P. B. and Briggs, A. (2018) Enhancing the value of the ASCO value framework. MDM Policy and Practice, 3(1), pp. 1-3. (doi: 10.1177/2381468318776223) (PMID:30288447) (PMCID:PMC6157426)
Grieve, E. , Hesselgreaves, H., Wu, O. , Chalkidou, K., Ruiz, F., Smith, P., Li, R., Morris, L. and Briggs, A. (2017) The Value of Health Technology Assessment: a mixed methods framework. F1000Research, 6, 2171. (doi: 10.7490/f1000research.1115169.1)
Jahoda, A. et al. (2017) Comparison of behavioural activation with guided self-help for treatment of depression in adults with intellectual disabilities: a randomised controlled trial. Lancet Psychiatry, 4(12), pp. 909-919. (doi: 10.1016/S2215-0366(17)30426-1) (PMID:29153873) (PMCID:PMC5714593)
Hoogendoorn, M., Feenstra, T. L., Boland, M., Briggs, A. H. , Borg, S., Jansson, S.-A., Risebrough, N., Slejko, J. and Rutten-van Mölken, M. P.M.H. (2017) Prediction models for exacerbations in different COPD patient populations: comparing results of five large data sources. International Journal of Chronic Obstructive Pulmonary Disease, 12, pp. 3183-3194. (doi: 10.2147/COPD.S142378) (PMID:29138546)
Leyland, A. H. , Ouédraogo, S., Nam, J., Bond, L., Briggs, A. H. , Gray, R., Wood, R. and Dundas, R. (2017) Evaluation of health in pregnancy grants in Scotland: a natural experiment using routine data. Public Health Research, 5(6), (doi: 10.3310/phr05060) (PMID:29035487)
Quayyum, Z., Briggs, A. , Robles-Zurita, J., Oldroyd, K., Zeymer, U., Desch, S., de Waha, S. and Thiele, H. (2017) Protocol for an economic evaluation of the randomised controlled trial of culprit lesion only PCI versus immediate multivessel PCI in acute myocardial infarction complicated by cardiogenic shock: CULPRIT-SHOCK trial. BMJ Open, 7(8), e014849. (doi: 10.1136/bmjopen-2016-014849) (PMID:28821512) (PMCID:PMC5724099)
Morton, A., Adler, A. I., Bell, D., Briggs, A. , Brouwer, W., Claxton, K., Craig, N., Fischer, A., McGregor, P. and van Baal, P. (2017) Unrelated future costs and unrelated future benefits: reflections on NICE Guide to the Methods of Technology Appraisal. Health Economics, 25(8), pp. 933-938. (doi: 10.1002/hec.3366) (PMID:27374115)
Claes, J. et al. (2017) PATHway I: design and rationale for the investigation of the feasibility, clinical effectiveness and cost-effectiveness of a technology-enabled cardiac rehabilitation platform. BMJ Open, 7(6), e016781. (doi: 10.1136/bmjopen-2017-016781) (PMID:28667228) (PMCID:PMC5726129)
Briggs, A. H. et al. (2017) Development of the Galaxy Chronic Obstructive Pulmonary Disease (COPD) model using data from ECLIPSE: internal validation of a linked-equations cohort model. Medical Decision Making, 37(4), pp. 469-480. (doi: 10.1177/0272989X16653118) (PMID:27317436)
Exuzides, A. et al. (2017) Statistical modeling of disease progression for chronic obstructive pulmonary disease using data from the ECLIPSE study. Medical Decision Making, 37(4), pp. 453-468. (doi: 10.1177/0272989X15610781) (PMID:26449490)
Negrín, M. A., Nam, J. and Briggs, A. H. (2017) Bayesian solutions for handling uncertainty in survival extrapolation. Medical Decision Making, 37(4), pp. 367-376. (doi: 10.1177/0272989X16650669) (PMID:27281336)
Williams, C., Lewsey, J. D. , Briggs, A. H. and Mackay, D. F. (2017) Cost-effectiveness analysis in R using a multi-state modelling survival analysis framework: a tutorial. Medical Decision Making, 37(4), pp. 340-352. (doi: 10.1177/0272989X16651869) (PMID:27281337) (PMCID:PMC5424858)
Williams, C., Lewsey, J. D. , Mackay, D. F. and Briggs, A. H. (2017) Estimation of survival probabilities for use in cost-effectiveness analysis: a comparison of a multi-state modelling survival analysis approach with partitioned survival and Markov decision-analytic modelling. Medical Decision Making, 37(4), pp. 427-439. (doi: 10.1177/0272989X16670617) (PMID:27698003) (PMCID:PMC5424853)
Gumley, A. et al. (2017) A parallel group randomised open blinded evaluation of Acceptance and Commitment Therapy for depression after psychosis: pilot trial outcomes (ADAPT). Schizophrenia Research, 183, pp. 143-150. (doi: 10.1016/j.schres.2016.11.026) (PMID:27894822)
Crombie, I. K. et al. (2017) Modifying Alcohol Consumption to Reduce Obesity (MACRO): development and feasibility trial of a complex community-based intervention for men. Health Technology Assessment, 21(19), (doi: 10.3310/hta21190) (PMID:28414020)
Briggs, A. H. , Bhatt, D. L., Scirica, B. M., Raz, I., Johnston, K. M., Szabo, S. M., Bergenheim, K., Mukherjee, J., Hirshberg, B. and Mosenzon, O. (2017) Health-related quality-of-life implications of cardiovascular events in individuals with type 2 diabetes mellitus: A subanalysis from the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-TIMI 53 trial. Diabetes Research and Clinical Practice, 130, pp. 24-33. (doi: 10.1016/j.diabres.2016.12.019) (PMID:28554140)
Sullivan, F.M. et al. (2017) Detection in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer using the EarlyCDT®-Lung Test (ECLS): study protocol for a randomized controlled trial. BMC Cancer, 17, 187. (doi: 10.1186/s12885-017-3175-y) (PMID:28284200) (PMCID:PMC5346215)
Hoogendoorn, M., Feenstra, T. L., Asukai, Y., Briggs, A. H. , Hansen, R. N., Leidl, R., Risebrough, N., Samyshkin, Y., Wacker, M. and Rutten-van Mölken, M. P.M.H. (2017) External validation of health economic decision models for chronic obstructive pulmonary disease (COPD): report of the third COPD modeling meeting. Value in Health, 20(3), pp. 397-403. (doi: 10.1016/j.jval.2016.10.016) (PMID:28292484)
Bousquet, J. et al. (2017) Erratum to: scaling up strategies of the chronic respiratory disease programme of the European innovation partnership on active and healthy ageing (Action Plan B3: Area 5). Clinical and Translational Allergy, 7, 5. (doi: 10.1186/s13601-016-0135-6) (PMID:28239450) (PMCID:PMC5319069)
Parker, C., Woods, B., Eaton, J., Ma, E., Selby, R., Benson, E., Engstrom, A., Sajosi, P., Briggs, A. and Bonthapally, V. (2017) Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland. Journal of Medical Economics, 20(1), pp. 8-18. (doi: 10.1080/13696998.2016.1219358) (PMID:27472034)
Tabberer, M., Gonzalez-McQuire, S., Muellerova, H., Briggs, A. , Rutten-van Molken, M., Chambers, M. and Lomas, D. A. (2017) Development of a conceptual model of disease progression for use in economic modeling of chronic obstructive pulmonary disease. Medical Decision Making, 37(4), pp. 440-452. (doi: 10.1177/0272989X16662009) (PMID:27486218)
Bousquet, J. et al. (2016) ARIA 2016: care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. Clinical and Translational Allergy, 6, 47. (doi: 10.1186/s13601-016-0137-4) (PMID:28050247) (PMCID:PMC5203711)
Briggs, A. (2016) A view from the bridge: health economic evaluation - a value-based framework? Health Economics, 25(12), pp. 1499-1502. (doi: 10.1002/hec.3448) (PMID:27870333)
Wilkinson, T. et al. (2016) The international decision support initiative reference case for economic evaluation: an aid to thought. Value in Health, 19(8), pp. 921-928. (doi: 10.1016/j.jval.2016.04.015) (PMID:27987641)
Briggs, A. H. , Parfrey, P. S., Khan, N., Tseng, S., Dehmel, B., Kubo, Y., Chertow, G. M. and Belozeroff, V. (2016) Analyzing health-related quality of life in the evolve trial: the joint impact of treatment and clinical events. Medical Decision Making, 36(8), pp. 965-972. (doi: 10.1177/0272989x16638312) (PMID:26987347)
Wildman, J., McMeekin, P., Grieve, E. and Briggs, A. (2016) Economic evaluation of integrated new technologies for health and social care: Suggestions for policy makers, users and evaluators. Social Science and Medicine, 169, pp. 141-148. (doi: 10.1016/j.socscimed.2016.09.033) (PMID:27721138)
Bouttell, J. , Lewsey, J. , Geue, C. , Antony, G., Briggs, A. , McCartney, G., Hutchinson, S., Graham, L. and Heydtmann, M. (2016) The SCottish alcoholic liver disease evaluation: a population-level matched cohort study of hospital-based costs, 1991-2011. PLoS ONE, 11(10), e0162980. (doi: 10.1371/journal.pone.0162980) (PMID:27783619) (PMCID:PMC5082635)
Willett, K. et al. (2016) Close contact casting vs surgery for initial treatment of unstable ankle fractures in older adults: a randomized clinical trial. JAMA: Journal of the American Medical Association, 316(14), pp. 1455-1463. (doi: 10.1001/jama.2016.14719) (PMID:27727383)
Keene, D. J. et al. (2016) The Ankle Injury Management (AIM) trial: a pragmatic, multicentre, equivalence randomised controlled trial and economic evaluation comparing close contact casting with open surgical reduction and internal fixation in the treatment of unstable ankle fractures in patients aged over 60 years. Health Technology Assessment, 20(75), (doi: 10.3310/hta20750) (PMID:27735787)
Städler, N., Shang, A., Bosch, F., Briggs, A. , Goede, V., Berthier, A., Renaudin, C. and Leblond, V. (2016) A systematic review and network meta-analysis to evaluate the comparative efficacy of interventions for unfit patients with chronic lymphocytic leukemia. Advances in Therapy, 33(10), pp. 1814-1830. (doi: 10.1007/s12325-016-0398-2) (PMID:27535291)
Hoogendoorn, M. et al. (2016) Patient heterogeneity in health economic decision models for chronic obstructive pulmonary disease: are current models suitable to evaluate personalized medicine? Value in Health, 19(6), pp. 800-810. (doi: 10.1016/j.jval.2016.04.002) (PMID:27712708)
Wolowacz, S. E., Briggs, A. , Belozeroff, V., Clarke, P., Doward, L., Goeree, R., Lloyd, A. and Norman, R. (2016) Estimating health-state utility for economic models in clinical studies: an ISPOR good research practices task force report. Value in Health, 19(6), pp. 704-719. (doi: 10.1016/j.jval.2016.06.001) (PMID:27712695)
Bousquet, J. et al. (2016) Scaling up strategies of the chronic respiratory disease programme of the European innovation partnership on active and healthy ageing (Action Plan B3: Area 5). Clinical and Translational Allergy, 2016(6), 29. (doi: 10.1186/s13601-016-0116-9) (PMID:27478588) (PMCID:PMC4966705)
Lawson, K., Briggs, A. , Lewsey, J. , Ford, I. , Watt, G., Tunstall-Pedoe, H., Woodward, M., Ritchie, L., Kent, S. and Neilson, M. (2016) A cardiovascular disease policy model: part 2 – preparing for economic evaluation and to assess health inequalities. Open Heart, 3(1), e000140. (doi: 10.1136/openhrt-2014-000140) (PMID:27335653) (PMCID:PMC4908904)
Lee, M. M.Y. et al. (2016) Non-invasive versus invasive management in patients with prior coronary artery bypass surgery with a non-ST segment elevation acute coronary syndrome: study design of the pilot randomised controlled trial and registry (CABG-ACS). Open Heart, 3(1), e000371. (doi: 10.1136/openhrt-2015-000371) (PMID:27110377) (PMCID:PMC4838768)
Boyd, K. A. , Briggs, A. H. , Bauld, L., Sinclair, L. and Tappin, D. (2016) Are financial incentives cost-effective to support smoking cessation during pregnancy? Addiction, 111(2), pp. 360-370. (doi: 10.1111/add.13160) (PMID:26370095)
Briggs, A. and Nugent, R. (2016) Editorial. Health Economics, 25(S1), pp. 6-8. (doi: 10.1002/hec.3321) (PMID:26804358)
Thiele, H. et al. (2016) Multivessel versus culprit lesion only percutaneous revascularization plus potential staged revascularization in patients with acute myocardial infarction complicated by cardiogenic shock: design and rationale of CULPRIT-SHOCK trial. American Heart Journal, 172, pp. 160-169. (doi: 10.1016/j.ahj.2015.11.006) (PMID:26856228)
Becker, U., Briggs, A. H. , Moreno, S. G., Ray, J. A., Ngo, P. and Samanta, K. (2016) Cost-effectiveness model for chemoimmunotherapy options in patients with previously untreated chronic lymphocytic leukemia unsuitable for full-dose fludarabine-based therapy. Value in Health, 19(4), pp. 374-382. (doi: 10.1016/j.jval.2015.12.018) (PMID:27325329)
Gumley, A. et al. (2016) A parallel group randomised open blinded evaluation of Acceptance and Commitment Therapy for Depression After Psychosis: A Pilot Trial Protocol (ADAPT). Psychosis, 8(2), pp. 143-155. (doi: 10.1080/17522439.2015.1100669)
Tremblay, G., Livings, C., Crowe, L., Kapetanakis, V. and Briggs, A. (2016) Determination of the most appropriate method for extrapolating overall survival data from a placebo-controlled clinical trial of lenvatinib for progressive, radioiodine-refractory differentiated thyroid cancer. ClinicoEconomics and Outcomes Research, 2016(8), pp. 323-333. (doi: 10.2147/CEOR.S107498) (PMID:27418847) (PMCID:PMC4934460)
Jahoda, A. , Melville, C. , Cooper, S.-A. , Hastings, R., Briggs, A. , Dagnan, D., Hatton, C., McConnachie, A. , Williams, C. and Jones, R. P. (2015) BEAT-IT: a randomised controlled trial comparing a behavioural activation treatment for depression in adults with intellectual disabilities with an attention control: summary of study protocol. Trials, 16, 595. (doi: 10.1186/s13063-015-1103-5) (PMID:26714891) (PMCID:PMC4696180)
Belozeroff, V., Chertow, G. M., Graham, C. N., Dehmel, B., Parfrey, P. S. and Briggs, A. H. (2015) Economic evaluation of cinacalcet in the United States: the EVOLVE trial. Value in Health, 18(8), pp. 1079-1087. (doi: 10.1016/j.jval.2015.08.007) (PMID:26686794)
Nam, J. et al. (2015) Fractional flow reserve (FFR) versus angiography in guiding management to optimise outcomes in non-ST segment elevation myocardial infarction (FAMOUS-NSTEMI) developmental trial: cost-effectiveness using a mixed trial- and model-based methods. Cost Effectiveness and Resource Allocation, 2015(13), 19. (doi: 10.1186/s12962-015-0045-9) (PMID:26578850) (PMCID:PMC4647286)
McMurray, J.J. et al. (2015) A new cost-effectiveness modelling approach in chronic heart failure with reduced ejection fraction - PCV118. Value in Health, 18(7), A394. (doi: 10.1016/j.jval.2015.09.887) (PMID:26532224)
Bousquet, J. et al. (2015) MACVIA-ARIA sentinel networK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. Allergy, 70(11), pp. 1372-1392. (doi: 10.1111/all.12686) (PMID:26148220)
Reed, S. D. et al. (2015) Tools for economic analysis of patient management interventions in heart failure cost-effectiveness model: a web-based program designed to evaluate the cost-effectiveness of disease management programs in heart failure. American Heart Journal, 170(5), pp. 951-960. (doi: 10.1016/j.ahj.2015.08.015) (PMID:26542504)
Boyd, K. A. , Jones, R. J. , Paul, J. , Birrell, F., Briggs, A. H. and Leung, H. Y. (2015) Decision-analytic cost-effectiveness model to compare prostate cryotherapy to androgen deprivation therapy for treatment of radiation recurrent prostate cancer. BMJ Open, 5(10), e007925. (doi: 10.1136/bmjopen-2015-007925) (PMID:26482768) (PMCID:PMC4611206)
Lorgelly, P. K., Lorimer, K., Fenwick, E. A.L., Briggs, A. H. and Anand, P. (2015) Operationalising the capability approach as an outcome measure in public health: the development of the OCAP-18. Social Science and Medicine, 142, pp. 68-81. (doi: 10.1016/j.socscimed.2015.08.002) (PMID:26291444)
Old, O., Moayyedi, P., Love, S., Roberts, C., Hapeshi, J., Foy, C., Stokes, C., Briggs, A. , Jankowski, J. and Barr, H. (2015) Barrett's oesophagus surveillance versus endoscopy at need study (BOSS): protocol and analysis plan for a multicentre randomized controlled trial. Journal of Medical Screening, 22(3), pp. 158-164. (doi: 10.1177/0969141315575052) (PMID:25767103)
Wolowacz, S., Pearson, I., Shannon, P., Chubb, B., Gundgaard, J., Davies, M. and Briggs, A. (2015) Development and validation of a cost-utility model for Type 1 diabetes mellitus. Diabetic Medicine, 32(8), pp. 1023-1035. (doi: 10.1111/dme.12663) (PMID:25484028)
Devereux, G. et al. (2015) Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial. Trials, 16, 267. (doi: 10.1186/s13063-015-0782-2) (PMID:26058585) (PMCID:PMC4465017)
Govan, L. , Wu, O. , Lindsay, R. and Briggs, A. (2015) How do diabetes models measure up? A review of diabetes economic models and ADA guidelines. Journal of Health Economics and Outcomes Research, 3(2), pp. 132-152.
Husereau, D., Drummond, M., Petrou, S., Greenberg, D., Mauskopf, J., Augustovski, F., Briggs, A. H. , Moher, D., Loder, E. and Carswell, C. (2015) Reply to Roberts et al.: CHEERS is sufficient for reporting cost-benefit analysis, but may require further elaboration. PharmacoEconomics, 33(5), pp. 535-536. (doi: 10.1007/s40273-015-0277-8) (PMID:25893576)
Stollenwerk, B., Lhachimi, S. K., Briggs, A. , Fenwick, E., Caro, J. J., Siebert, U., Danner, M. and Gerber-Grote, A. (2015) Communicating the parameter uncertainty in the IQWiG efficiency frontier to decision-makers. Health Economics, 24(4), pp. 481-490. (doi: 10.1002/hec.3041) (PMID:24590819)
Geue, C. , Lorgelly, P., Lewsey, J. , Hart, C. and Briggs, A. (2015) Hospital expenditure at the end-of-life: what are the impacts of health status and health risks? PLoS ONE, 10(3), e0119035. (doi: 10.1371/journal.pone.0119035) (PMID:25746728) (PMCID:PMC4352086)
Ramsey, S. D., Willke, R. J., Glick, H., Reed, S. D., Augustovski, F., Jonsson, B., Briggs, A. and Sullivan, S. D. (2015) Cost-effectiveness analysis alongside clinical trials II—An ISPOR Good Research Practices Task Force Report. Value in Health, 18(2), pp. 161-172. (doi: 10.1016/j.jval.2015.02.001) (PMID:25773551)
Layland, J. et al. (2015) Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-ST-segment elevation myocardial infarction: the British Heart Foundation FAMOUS-NSTEMI randomized trial. European Heart Journal, 36(2), pp. 100-111. (doi: 10.1093/eurheartj/ehu338) (PMID:25179764) (PMCID:PMC4291317)
Cook, J. A. et al. (2015) Specifying the target difference in the primary outcome for a randomised controlled trial: guidance for researchers. Trials, 16(1), 12. (doi: 10.1186/s13063-014-0526-8) (PMID:25928502) (PMCID:PMC4302137)
Haines, P., Tremblay, G. and Briggs, A. (2015) A criterion-based approach for the systematic and transparent extrapolation of clinical trial survival data. Journal of Health Economics and Outcomes Research, 2(2), pp. 147-160.
Lewsey, J. et al. (2015) Temporal trends and risk factors for readmission for infections, gastrointestinal and immobility complications after an incident hospitalisation for stroke in Scotland between 1997 and 2005. BMC Neurology, 15(3), (doi: 10.1186/s12883-014-0257-1) (PMID:25591718) (PMCID:PMC4320501)
Logue, J. et al. (2015) SurgiCal Obesity Treatment Study (SCOTS): protocol for a national prospective cohort study of patients undergoing bariatric surgery in Scotland. BMJ Open, 5(5), e008106. (doi: 10.1136/bmjopen-2015-008106) (PMID:26002692) (PMCID:PMC4442215)
Welsh, P. et al. (2014) Contrasting associations of insulin resistance with diabetes, cardiovascular disease and all-cause mortality in the elderly: PROSPER long-term follow-up. Diabetologia, 57(12), pp. 2513-2520. (doi: 10.1007/s00125-014-3383-9) (PMID:25264116)
Geue, C. , Briggs, A. , Lewsey, J. and Lorgelly, P. (2014) Population ageing and healthcare expenditure projections: new evidence from a time to death approach. European Journal of Health Economics, 15(5), pp. 885-896. (doi: 10.1007/s10198-013-0543-7)
Boyd, K.A. , Briggs, A.H. , Bauld, L., Sinclair, L. and Tappin, D. (2014) Are financial incentives cost-effective for smoking cessation amongst pregnant women? European Journal of Public Health, 24(S2), p. 146. (doi: 10.1093/eurpub/cku162.090)
Bousquet, J. et al. (2014) Integrated care pathways for airway diseases (AIRWAYS-ICPs). European Respiratory Journal, 44(2), pp. 304-323. (doi: 10.1183/09031936.00014614)
Hoogendoorn, M. et al. (2014) Cost-effectiveness models for chronic obstructive pulmonary disease: cross-model comparison of hypothetical treatment scenarios. Value in Health, 17(5), pp. 525-536. (doi: 10.1016/j.jval.2014.03.1721)
Cook, J. A., Hislop, J. M., Altman, D. G., Briggs, A. H. , Fayers, P. M., Norrie, J. D., Ramsay, C. R., Harvey, I. M. and Vale, L. D. (2014) Use of methods for specifying the target difference in randomised controlled trial sample size calculations: Two surveys of trialists' practice. Clinical Trials, 11(3), pp. 300-308. (doi: 10.1177/1740774514521907) (PMID:24603006)
Boyd, K.A. , Jones, R.J. , Paul, J. , Briggs, A. and Leung, H.Y. (2014) A decision-analytic cost-effectiveness model to compare treatment options for radiation recurrent prostate cancer against androgen deprivation therapy. British Journal of Surgery, 101(s4), p. 59. (doi: 10.1002/bjs.9510)
Cooke, J. A. et al. (2014) Assessing methods to specify the target difference for a randomised controlled trial: DELTA (Difference ELicitation in TriAls) review. Health Technology Assessment, 18(28), v-vi, 1. (doi: 10.3310/hta18280)
Levy, A. R., Briggs, A. H. , Johnston, K., MacLean, J. R., Yuan, Y., L’Italien, G. J., Kalsekar, A. and Schnitzler, M. A. (2014) Projecting long-term graft and patient survival after transplantation. Value in Health, 17(2), pp. 254-260. (doi: 10.1016/j.jval.2014.01.001)
Caro, J.J., Eddy, D. M., Kan, H., Kaltz, C., Patel, B., Eldessouki, R. and Briggs, A. H. (2014) Questionnaire to assess relevance and credibility of modeling studies for informing health care decision making: an ISPOR-AMCP-NPC good practice task force report. Value in Health, 17(2), pp. 174-182. (doi: 10.1016/j.jval.2014.01.003)
Looker, H.C. et al. (2014) Risk stratification for diabetic eye screening: reply to Stratton I. M. and Aldington S. J. Diabetologia, 57(1), pp. 260-261. (doi: 10.1007/s00125-013-3099-2)
Samyshkin, Y., Kotchie, R. W., Mörk, A.-C., Briggs, A. H. and Bateman, E. D. (2014) Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom. European Journal of Health Economics, 15(1), pp. 69-82. (doi: 10.1007/s10198-013-0456-5) (PMID:23392624) (PMCID:PMC3889819)
Campbell, J. D., McQueen, R. B. and Briggs, A. (2014) The “E” in cost-effectiveness analyses. A case study of omalizumab efficacy and effectiveness for cost-effectiveness analysis evidence. Annals of the American Thoracic Society, 11(Sup 2), S105-S111. (doi: 10.1513/AnnalsATS.201309-295RM)
Dundas, R. , Ouédraogo, S., Bond, L., Briggs, A.H. , Chalmers, J., Gray, R., Wood, R. and Leyland, A.H. (2014) Evaluation of Health in Pregnancy grants in Scotland: a protocol for a natural experiment. BMJ Open, 4(10), e006547. (doi: 10.1136/bmjopen-2014-006547)
Hislop, J. et al. (2014) Methods for specifying the target difference in a randomised controlled trial: the Difference ELicitation in TriAls (DELTA) Systematic Review. PLoS Medicine, 11(5), e1001645. (doi: 10.1371/journal.pmed.1001645)
Lewsey, J.D. et al. (2014) A cardiovascular disease policy model that predicts life expectancy taking into account socioeconomic deprivation. Heart, 101(3), pp. 201-208. (doi: 10.1136/heartjnl-2014-305637)
Munge, K. and Briggs, A. H. (2014) The progressivity of health-care financing in Kenya. Health Policy and Planning, 29(7), pp. 912-920. (doi: 10.1093/heapol/czt073)
Willett, K. et al. (2014) Ankle Injury Management (AIM): design of a pragmatic multi-centre equivalence randomised controlled trial comparing close contact casting (CCC) to open surgical reduction and internal fixation (ORIF) in the treatment of unstable ankle fractures in patients over 60 years. BMC Musculoskeletal Disorders, 15, 79. (doi: 10.1186/1471-2474-15-79) (PMID:24621174) (PMCID:PMC4234276)
Layland, J. et al. (2013) TCT-84 Fractional Flow Reserve versus Angiography in Guiding Management to Optimize Outcomes in Non-ST Elevation Myocardial Infarction (FAMOUS - NSTEMI) Clinical Trial: Study Design and Baseline Characteristics of Randomized Participants. Journal of the American College of Cardiology, 62(18), B27. (doi: 10.1016/j.jacc.2013.08.1636)
Berry, C. et al. (2013) Fractional flow reserve versus angiography in guiding management to optimize outcomes in non–ST-elevation myocardial infarction (FAMOUS-NSTEMI): rationale and design of a randomized controlled clinical trial. American Heart Journal, 166(4), 662-668.e3. (doi: 10.1016/j.ahj.2013.07.011)
Jaime Caro, J., Eddy, D.M., Hollingworth, W., Tsevat, J., McDonald, K.M., Wong, J.B., Briggs, A.H. , Siebert, U. and Kuntz, K.M. (2013) ISPOR-SMDM task force’s recommendations for good modeling practices—reply to letter to the editor by Corro Ramos. Value in Health, 16(6), p. 1108. (doi: 10.1016/j.jval.2013.06.016)
Looker, H.C. et al. (2013) Predicted impact of extending the screening interval for diabetic retinopathy: the Scottish Diabetic Retinopathy Screening programme. Diabetologia, 56(8), pp. 1716-1725. (doi: 10.1007/s00125-013-2928-7)
Roberts, N.J., Lewsey, J.D. , Gillies, M., Briggs, A.H. , Belozeroff, V., Globe, D.R., Chiou, C.-F., Lin, S.-L. and Globe, G. (2013) Time trends in 30 day case-fatality following hospitalisation for asthma in adults in Scotland: a retrospective cohort study from 1981-2009. Respiratory Medicine, 107(8), pp. 1172-1177. (doi: 10.1016/j.rmed.2013.04.004)
Tigbe, W.W., Briggs, A.H. and Lean, M.E.J. (2013) A patient-centred approach to estimate total annual healthcare cost by body mass index in the UK Counterweight programme. International Journal of Obesity, 37(8), pp. 1135-1139. (doi: 10.1038/ijo.2012.186)
Garrison, L.P., Towse, A., Briggs, A. , de Pouvourville, G., Grueger, J., Mohr, P.E., Severens, J.L., Siviero, P. and Sleeper, M. (2013) Performance-based risk-sharing arrangements—good practices for design, implementation, and evaluation: report of the ispor good practices for performance-based risk-sharing arrangements task force. Value in Health, 16(5), pp. 703-719. (doi: 10.1016/j.jval.2013.04.011)
Hemingway, H. et al. (2013) Prognosis research strategy (PROGRESS) 1: a framework for researching clinical outcomes. British Medical Journal, 2013(346), e5595. (doi: 10.1136/bmj.e5595)
Riley, R. D. et al. (2013) Prognosis Research Strategy (PROGRESS) 2: prognostic factor research. PLoS Medicine, 10(2), e1001380. (doi: 10.1371/journal.pmed.1001380)
Murphy, A., Fenwick, E., Toff, W.D., Neilson, M.P., Berry, C. , Uren, N., Oldroyd, K.G. and Briggs, A.H. (2013) Transcatheter aortic valve implantation for severe aortic stenosis: the cost-effectiveness case for inoperable patients in the United Kingdom. International Journal of Technology Assessment in Health Care, 29(01), pp. 12-19. (doi: 10.1017/S0266462312000670)
Davies, C., Briggs, A. , Lorgelly, P., Garellick, G. and Malchau, H. (2013) The 'hazards' of extrapolating survival curves. Medical Decision Making, 33(3), pp. 369-380. (doi: 10.1177/0272989X12475091) (PMID:23457025)
Grutters, J.P.C., Sculpher, M., Briggs, A.H. , Severens, J.L., Candel, M.J., Stahl, J.E., de Ruysscher, D., Boer, A., Ramaekers, B.L.T. and Joore, M.A. (2013) Acknowledging patient heterogeneity in economic evaluation. PharmacoEconomics, 31(2), pp. 111-123. (doi: 10.1007/s40273-012-0015-4)
Husereau, D., Drummond, M., Petrou, S., Carswell, C., Moher, D., Greenberg, D., Augustovski, F., Briggs, A.H. , Mauskopf, J. and Loder, E. (2013) Consolidated Health Economic Evaluation Reporting Standards (CHEERS) - explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value in Health, 16(2), pp. 231-250. (doi: 10.1016/j.jval.2013.02.002)
Husereau, D., Drummond, M., Petrou, S., Carswell, C., Moher, D., Greenberg, D., Augustovski, F., Briggs, A.H. , Mauskopf, J. and Loder, E. (2013) Consolidated health economic evaluation reporting standards (CHEERS) statement. British Medical Journal, 346(f1049), (doi: 10.1136/bmj.f1049)
Lloyd, S.M. et al. (2013) Long-term effects of statin treatment in elderly people: Extended follow-up of the PROspective study of Pravastatin in the elderly at risk (PROSPER). PLoS ONE, 8(9), e72642. (doi: 10.1371/journal.pone.0072642) (PMID:24023757) (PMCID:PMC3759378)
Silveirinha de Oliveira, E., Aspinall, P., Briggs, A. , Cummins, S., Leyland, A. , Mitchell, R. , Roe, J. and Ward Thompson, C. (2013) How effective is the Forestry Commission Scotland's woodland improvement programme--'Woods In and Around Towns' (WIAT)--at improving psychological well-being in deprived urban communities? A quasi-experimental study. BMJ Open, 3(8), e003648. (doi: 10.1136/bmjopen-2013-003648) (PMID:23996826) (PMCID:PMC3758971)
Geue, C. , Lewsey, J. , Lorgelly, P., Govan, L. , Hart, C. and Briggs, A. (2012) Spoilt for choice: implications of costing hospital episode statistics. Health Economics, 21(10), pp. 1201-1216. (doi: 10.1002/hec.1785)
Briggs, A.H. , Weinstein, M.C., Fenwick, E.A.L., Karnon, J., Sculpher, M.J. and Paltiel, A.D. (2012) Model parameter estimation and uncertainty: a report of the ISPOR-SMDM modeling good research practices task force-6. Value in Health, 15(6), pp. 835-842. (doi: 10.1016/j.jval.2012.04.014)
Caro, J.J., Briggs, A.H. , Siebert, U. and Kuntz, K.M. (2012) modeling good research practices—overview: a report of the ISPOR-SMDM modeling good research practices task force-1. Value in Health, 15(6), pp. 796-803. (doi: 10.1016/j.jval.2012.06.012)
Wu, O. , Briggs, A. and MacIntyre, K. (2012) Mobile phone use for contacting emergency services in life-threatening circumstances. Journal of Emergency Medicine, 42(3), pp. 291-298. (doi: 10.1016/j.jemermed.2011.02.022)
Briggs, A. (2012) The ends justify the mean: outcome measures for estimating the value of new cancer therapies. Health Outcomes Research in Medicine, 3(1), e25-e26. (doi: 10.1016/j.ehrm.2012.01.001)
Briggs, A.H. , Weinstein, M.C., Fenwick, E.A.L., Karnon, J., Sculpher, M.J. and Paltiel, A.D. (2012) Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working group - 6. Medical Decision Making, 32(5), pp. 722-732. (doi: 10.1177/0272989X12458348)
Caro, J.J., Briggs, A.H. , Siebert, U. and Kuntz, K.M. (2012) Modeling good research practices - overview: a report of the ISPOR-SMDM modeling good research practices task force - 1. Medical Decision Making, 32(5), pp. 667-677. (doi: 10.1177/0272989X12454577)
Govan, L. et al. (2012) The effect of deprivation and HbA1c on admission to hospital for diabetic ketoacidosis in type 1 diabetes. Diabetologia, 55(9), pp. 2356-2360. (doi: 10.1007/s00125-012-2601-6)
Roberts, N.J., Boyd, K. , Briggs, A.H. , Caress, A.L. and Partridge, M.R. (2012) Nurse led versus lay educators support for those with asthma in primary care: a costing study. BMC Pulmonary Medicine, 12(52), (doi: 10.1186/1471-2466-12-52)
Tappin, D.M. et al. (2012) The cessation in pregnancy incentives trial (CPIT): study protocol for a randomized controlled trial. Trials, 13(113), (doi: 10.1186/1745-6215-13-113) (PMID:22818493) (PMCID:PMC3482147)
McLean, R.C., Briggs, A.H. , Slack, R., Zamvar, V., Berg, G.A., El-Shafei, H., Oldroyd, K.G. and Pell, J.P. (2011) Perioperative and long-term outcomes following aortic valve replacement: a population cohort study of 4124 consecutive patients. European Journal of Cardio-Thoracic Surgery, 40(6), pp. 1508-1514. (doi: 10.1016/j.ejcts.2011.01.088)
Boyd, K.A. , Briggs, A.H. , Fenwick, E., Norrie, J. and Stock, S. (2011) Power and sample size for cost-effectiveness analysis: fFN neonatal screening. Contemporary Clinical Trials, 32(6), pp. 893-901. (doi: 10.1016/j.cct.2011.07.007)
Govan, L. et al. (2011) Achieved levels of HbA1c and likelihood of hospital admission in people with type 1 diabetes in the Scottish population: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetes Care, 34(9), pp. 1992-1997. (doi: 10.2337/dc10-2099)
Macpherson, K.J. et al. (2011) Trends in incidence and in short term survival following a subarachnoid haemorrhage in Scotland, 1986 - 2005: a retrospective cohort study. BMC Neurology, 11(1), p. 38. (doi: 10.1186/1471-2377-11-38)
Price, M.J., Welton, N.J., Briggs, A.H. and Ades, A.E. (2011) Model averaging in the presence of structural uncertainty about treatment effects: influence on treatment decision and expected value of information. Value in Health, 14(2), pp. 205-218. (doi: 10.1016/j.jval.2010.08.001)
Starkie, H.J., Briggs, A.H. , Chambers, M.G. and Jones, P. (2011) Predicting EQ-5D Values Using the SGRQ. Value in Health, 14(2), pp. 354-360. (doi: 10.1016/j.jval.2010.09.011)
Bauld, L., Boyd, K. A. , Briggs, A. H. , Chesterman, J., Ferguson, J., Judge, K. and Hiscock, R. (2011) One-year outcomes and a cost-effectiveness analysis for smokers accessing group-based and pharmacy-led cessation services. Nicotine and Tobacco Research, 13(2), pp. 135-145. (doi: 10.1093/ntr/ntq222)
Barton, P., Andronis, L., Briggs, A. , McPherson, K. and Capewell, S. (2011) Effectiveness and cost effectiveness of cardiovascular disease prevention in whole populations: modelling study. British Medical Journal, 343, d4044. (doi: 10.1136/bmj.d4044)
Bousquet, J. et al. (2011) How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA2LEN statement. Allergy, 66(6), pp. 765-774. (doi: 10.1111/j.1398-9995.2011.02590.x)
Boyd, K.A. , Briggs, A. , Paul, J. , Iveson, T., Midgely, R., Harkin, A., Bates, G., Alexander, L. and Cassidy, J. (2011) Analysis of adverse events and quality of life data for an economic evaluation of adjuvant chemotherapy in colorectal cancer: when can we stop collecting? Trials, 12, A41. (doi: 10.1186/1745-6215-12-S1-A41)
Cummins, E., Asseburg, C., Punekar, Y.S., Shore, E., Morris, J., Briggs, A. and Fenwick, E.L. (2011) Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis. Value in Health, 14(1), pp. 15-23. (doi: 10.1016/j.jval.2010.10.016)
Govan, L. et al. (2011) Inpatient costs for people with type 1 and type 2 diabetes in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia, 54(8), pp. 2000-2008. (doi: 10.1007/s00125-011-2176-7)
Boyd, K.A. , Fenwick, E. and Briggs, A. (2010) Using an iterative approach to economic evaluation in the drug development process. Drug Development Research, 71(8), pp. 470-477. (doi: 10.1002/ddr.20421)
Mihaylova, B., Briggs, A. , O'Hagan, A. and Thompson, S.G. (2010) Review of statistical methods for analysing healthcare resources and costs. Health Economics, 20(8), pp. 897-916. (doi: 10.1002/hec.1653)
Lorgelly, P.K., Lawson, K.D., Fenwick, E.A.L. and Briggs, A.H. (2010) Outcome Measurement in Economic Evaluations of Public Health Interventions: a Role for the Capability Approach? International Journal of Environmental Research and Public Health, 7(5), pp. 2274-2289. (doi: 10.3390/ijerph7052274) (PMID:20623024) (PMCID:PMC2898049)
Briggs, A.H., Glick, H.A., Lozano-Ortega, G., Spencer, M., Calverley, P.M.A., Jones, P.W. and Vestbo, J. (2010) Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal, 35(3), pp. 532-539. (doi: 10.1183/09031936.00153108)
Briggs, A. , Ritchie, K., Fenwick, E., Chalkidou, K. and Littlejohns, P. (2010) Access with evidence development in the UK past experience, current initiatives and future potential. PharmacoEconomics, 28(2), pp. 163-170. (doi: 10.2165/11531410-000000000-00000)
Lorgelly, P.K. et al. (2010) An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial. European Journal of Heart Failure, 12(1), pp. 66-74. (doi: 10.1093/eurjhf/hfp172)
Briggs, A.H. (2010) Transportability of comparative effectiveness and cost-effectiveness between countries. Value in Health, 13, S22-S25. (doi: 10.1111/j.1524-4733.2010.00751.x)
Campbell, H.E., Gray, A.M., Harris, A.L., Briggs, A.H. and Taylor, M.A. (2010) Estimation and external validation of a new prognostic model for predicting recurrence-free survival for early breast cancer patients in the UK. British Journal of Cancer, 103(6), pp. 776-786. (doi: 10.1038/sj.bjc.6605863)
Crott, R. and Briggs, A. (2010) Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences. European Journal of Health Economics, 11(4), pp. 427-434. (doi: 10.1007/s10198-010-0233-7)
Dolan, G.P., Stone, D.H. and Briggs, A. (2010) A systematic review of continuous performance task research in children prenatally exposed to alcohol. Alcohol and Alcoholism, 45(1), pp. 30-38. (doi: 10.1093/alcalc/agp062)
Hollingworth, W., Campbell, J.D., Kowalski, J., Ravelo, A., Girod, I., Briggs, A. and Sullivan, S.D. (2010) Exploring the impact of changes in neurogenic urinary incontinence frequency and condition-specific quality of life on preference-based outcomes. Quality of Life Research, 19(3), pp. 323-331. (doi: 10.1007/s11136-010-9590-z)
Johnston, K.M., Levy, A.R., Lima, V.D., Hogg, R.S., Tyndall, M.W., Gustafson, P., Briggs, A.H. and Montaner, J.S. (2010) Expanding access to HAART: a cost-effective approach for treating and preventing HIV. AIDS, 24(12), pp. 1929-1935. (doi: 10.1097/QAD.0b013e32833af85d)
Langhorne, P. et al. (2010) Estimating the impact of stroke unit care in a whole population: an epidemiological study using routine data. Journal of Neurology, Neurosurgery and Psychiatry, 81(2), pp. 1301-1305. (doi: 10.1136/jnnp.2009.195131)
Lewsey, J. et al. (2010) Temporal trends in hospitalisation for stroke recurrence following incident hospitalisation for stroke in Scotland. BMC Medicine, 8, p. 23. (doi: 10.1186/1741-7015-8-23)
Levy, A., Harrigan, B., Johnston, K. and Briggs, A. (2009) Comparative effectiveness research through the looking glass. Medical Decision Making, 29(6), NP6-NP8. (doi: 10.1177/0272989X09351590)
Lewsey, J. et al. (2009) Age- and sex-specific trends in fatal incidence and hospitalized incidence of stroke in Scotland, 1986 to 2005. Circulation: Cardiovascular Quality and Outcomes, 2(5), pp. 475-483. (doi: 10.1161/CIRCOUTCOMES.108.825968)
Jacobs-van der Bruggen, M. A. M., van Baal, P. H., Hoogenveen, R. T., Feenstra, T. L., Briggs, A. H. , Lawson, K., Feskens, E. J. M. and Baan, C. A. (2009) Cost-effectiveness of lifestyle modification in diabetes patients. Diabetes Care, 32(8), pp. 1453-1458. (doi: 10.2337/dc09-0363)
Wu, O., Levy, A.R., Briggs, A., Lewis, G. and Jardine, A. (2009) Acute rejection and chronic nephropathy: a systematic review of the literature. Transplantation, 87(9), pp. 1330-1339. (doi: 10.1097/TP.0b013e3181a236e0)
Lewsey, J.D. et al. (2009) Sex differences in incidence, mortality, and survival in individuals with stroke in Scotland, 1986 to 2005. Stroke, 40(4), pp. 1038-1043. (doi: 10.1161/STROKEAHA.108.542787)
Mihaylova, B., Briggs, A., Hlatky, M., Armitage, J., Parish, S., Gray, A. and Collins, R. (2009) Statin cost-effectiveness in the United States for people at different vascular risk levels. Circulation: Cardiovascular Quality and Outcomes, 2(2), pp. 65-72. (doi: 10.1161/CIRCOUTCOMES.108.808469)
Boyd, K.A. and Briggs, A.H. (2009) Cost-effectiveness of pharmacy and group behavioural support smoking cessation services in Glasgow. Addiction, 104(2), pp. 317-325. (doi: 10.1111/j.1360-0443.2008.02449.x)
Levy, A.R., Szabo, S., Briggs, A. , Pleil, A., Davie, A., Zlateva, G. and Javitt, J. (2009) Joint assessment of intended and unintended effects of medications: an example using vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration. Journal of Ophthalmology, 2009, 540431. (doi: 10.1155/2009/540431) (PMID:20339464) (PMCID:PMC2836847)
Barton, G.R., Briggs, A.H. and Fenwick, E.A.L. (2008) Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). Value in Health, 11(5), pp. 886-897. (doi: 10.1111/j.1524-4733.2008.00358.x)
Levy, A.R., Kowdley, K., Iloeje, U.H., Tafesse, E., Mukherjee, J., Gish, R., Bzowej, N. and Briggs, A.H. (2008) The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value in Health, 11(3), pp. 527-538. (doi: 10.1111/j.1524-4733.2007.00297.x) (PMID:18179664)
Hirst, A., Dutton, S., Wu, O. , Briggs, A. , Edwards, C. , Waldenmaier, L., Maresh, M., Nicholson, A. and McPherson, K. (2008) A multi-centre retrospective cohort study comparing the efficacy, safety and cost-effectiveness of hysterectomy and uterine artery embolisation for the treatment of symptomatic uterine fibroids: the HOPEFUL study. Health Technology Assessment, 12(5),
Briggs, A.H. , Spencer, M., Wang, H., Mannino, D. and Sin, D.D. (2008) Development and validation of a prognostic index for health outcomes in chronic obstructive pulmonary disease. Archives of Internal Medicine, 168(1), pp. 71-79. (doi: 10.1001/archinternmed.2007.37)
Briggs, A., Wild, D., Lees, M., Reaney, M., Dursun, S., Parry, D. and Mukherjee, J. (2008) Impact of schizophrenia and schizophrenia treatment related adverse events on quality of life: direct utility elicitation. Health and Quality of Life Outcomes, 6(105), pp. 1-9. (doi: 10.1186/1477-7525-6-105)
Claxton, K., Briggs, A.H. , Buxton, M.J., Culyer, A.J., McCabe, C., Walker, S. and Sculpher, M.J. (2008) Value based pricing for NHS drugs: an opportunity not to be missed? British Medical Journal, 336(7638), pp. 251-254. (doi: 10.1136/bmj.39434.500185.25)
Eckerman, S., Briggs, A. and Willan, A.R. (2008) Health technology assessment in the cost-disutility plane. Medical Decision Making, 28(2), pp. 172-181. (doi: 10.1177/0272989X07312474)
Hirst, A., Dutton, S., Wu, O. , Briggs, A. , Edwards, C., Waldenmaier, L., Maresh, M., Nicholson, A. and McPherson, K. (2008) The HOPEFUL Study: a multi-centre retrospective cohort study comparing the efficacy, safety and cost-effectiveness of hysterectomy and uterine artery embolisation (UAE) for the treatment of symptomatic uterine fibroids. Health Technology Assessment, 123(5), pp. 1-248.
Starkie, H., Briggs, A.H. and Chamber, M.G. (2008) Pharmacoeconomics in COPD: lessons for the future. International Journal of COPD, 3(1), pp. 71-88.
Campbell, H., Briggs, A.H. , Buxton, M., Kim, L. and Thompson, S. (2007) The credibility of health economic models for health policy decision-making: the case of population screening for abdominal aortic aneurysm. Journal of Health Services Research and Policy, 12(1), pp. 11-17. (doi: 10.1258/135581907779497594)
Briggs, A. et al. (2007) Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. Heart, 93(9), pp. 1081-1086.
Culyer, A., McCabe, C., Briggs, A.H. , Claxton, K., Buxton, M., Akehurst, R., Sculpher, M.J. and Brazier, J. (2007) Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence. Journal of Health Services Research and Policy, 12(1), pp. 56-58.
Kim, L., Thompson, S., Briggs, A. , Buxton, M. and Campbell, H. (2007) How cost-effective is screening for abdominal aortic aneurysms? Journal of Medical Screening, 14(1), pp. 46-52.
Luc, G., Ades, A., Sutton, A., Cooper, N., BriggS, A. and Caldwell, D. (2007) Meta-analysis of mixed treatment comparisons at multiple follow-up times. Statistics in Medicine, 26, pp. 3681-3699. (doi: 10.1002/sim.2831)
Ossa, D.F., Briggs, A.H. , McIntosh, E. , Cowell, W., Littlewood, T. and Sculpher, M.J. (2007) Recombinant erythropoietin for chemotherapy-related anaemia: economic value and health-related quality-of-life assessment using direct utility elicitation and discrete choice experiment methods. PharmacoEconomics, 25(3), pp. 223-237.
Mihaylova, B., Briggs, A.H. , Armitage, J., Parish, S., Gray, A. and Collins, R. (2006) Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people. British Medical Journal, 333(7579), p. 1145. (doi: 10.1136/bmj.38993.731725.BE)
Briggs, A.H. , Bousquet, J., Wallace, M., Busse, W.W., Clark, T.J.H., Pedersen, S.E. and Baternan, E.D. (2006) Cost-effectiveness of asthma control: an economic appraisal of the GOAL study. Allergy, 61(5), pp. 531-536. (doi: 10.1111/j.1398-9995.2006.01038.x)
Briggs, A.H. and Levy, A.R. (2006) Pharmacoeconomics and pharmacoepidemiology - Curious bedfellows or a match made in heaven? PharmacoEconomics, 24, pp. 1079-1086.
Briggs, A.H. , Lozano-Ortega, G., Spencer, S., Bale, G., Spencer, M.D. and Burge, S. (2006) Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value in Health, 9(4), pp. 227-235. (doi: 10.1111/j.1524-4733.2006.00106.x)
Deckers, J., Goedhart, D., Boersma, E., Briggs, A. , Bertrand, M., Ferrari, R., Remme, W., Fox, K. and imoons, M. (2006) Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk. European Heart Journal, 27, pp. 796-801. (doi: 10.1093/eurheartj/ehi809)
Williams, C. et al. (2006) Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy. Health Technology Assessment, 10, 1-+.
Manca, A., Rice, N., Sculpher, M.J. and Briggs, A.H. (2005) Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models. Health Economics, 14(5), pp. 471-485. (doi: 10.1002/hec.914)
Claxton, K., Sculpher, M., McCabe, C., Briggs, A.H. , Akehurst, R., Buxton, M., Brazier, J. and O'Hagan, T. (2005) Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Economics, 14(4), pp. 339-347. (doi: 10.1002/hec.985)
Briggs, A.H. (2005) Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. Value in Health, 8(1), pp. 1-2. (doi: 10.1111/j.1524-4733.2005.08101.x)
Briggs, A.H. , Nixon, R., Dixon, S. and Thompson, S. (2005) Parametric modelling of cost data: some simulation evidence. Health Economics, 14(4), pp. 421-428. (doi: 10.1002/hec.941)
Briggs, A. (2005) Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. Value in Health, 8(1), pp. 1-2.
Clarke, P., Gray, A., Briggs, A. , Stevens, R., Matthews, D. and Holman, R. (2005) Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia, 48(5), pp. 868-877.
Gagnon, Y., Levy, A., Spencer, M., Hurley, J., Frost, F., Mapel, D. and Briggs, A. (2005) Economic evaluation of treating chronic obstructive pulmonary disease with inhaled corticosteroids and long-acting beta2-agonists in a health maintenance organization. Respiratory Medicine, 99(12), pp. 1534-1545.
Manca, A., Rice, N., Sculpher, M. and Briggs, A. (2005) Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models.[erratum appears in Health Econ. Health Economics, 14(5), pp. 471-485.
Mihaylova, B., Briggs, A. , Armitage, J., Parish, S., Gary, A. and Collins, R. (2005) Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals. Lancet, 365(9473), pp. 1779-1785.
O'Hagan, T. et al. (2005) Incorporation of uncertainty in health economic modelling studies. PharmacoEconomics, 23(6), pp. 529-536.
Ramsey, S. et al. (2005) Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value in Health, 8(5), pp. 521-533.
Reed, S. et al. (2005) Conducting economic evaluations alongside multinational clinical trials: toward a research consensus. American Heart Journal, 149(3), pp. 434-443.
Spencer, M.D., Briggs, A.H. , Grossman, R.J. and Rance, L. (2005) Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. PharmacoEconomics, 23(6), pp. 619-637.
Clarke, P.M., Gray, A.M., Briggs, A. , Farmer, A.J., Fenn, P.,, Stevenson, R.J., Matthews, D.R., Stratton, I.M. and Holman, R.R. (2004) A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia, 47(10), pp. 1747-1759. (doi: 10.1007/s00125-004-1527-z)
Briggs, A.H. (2004) Statistical approaches to handling uncertainty in health economic evaluation. Psychiatrist, 16(6), pp. 551-561.
Briggs, A. (2004) Statistical approaches to handling uncertainty in health economic evaluation. [29 refs]. European Journal of Gastroenterology and Hepatology, 16(6), pp. 551-561.
Briggs, A. , Sculpher, M., Dawson, J. , Fitzpatrick, R., Murray, D. and Malchau, H. (2004) The Use of Probabilistic Decision Models in Technology Assessment: The Case of Total Hip Replacement. Applied Health Economics and Health Policy, 3(2), pp. 78-79.
Clarke, P., Gray, A., Briggs, A., Farmer, A., Fenn, P., Stevens, R., Matthews, D., Stratton, I. and Holman, R. (2004) A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia, 47, pp. 1747-1759. (doi: 10.1007/s00125-004-1527-z)
Gagnon, Y., Levy, A., Iloeje, U. and Briggs, A. (2004) Treatment costs in Canada of health conditions resulting from chronic Hepatitis B infection. Journal of Clinical Gastroenterology, 38(Suppl), S179-S186.
Willan, A., Briggs, A. and Hoch, J. (2004) Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. Health Economics, 13(5), pp. 461-475.
Clarke, P., Gray, A., Legood, R., Briggs, A. and Holman, R. (2003) The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabetic Medicine, 20(6), pp. 442-450. (doi: 10.1046/j.1464-5491.2003.00972.x)
Reed, S.D., Dillingham, P.W., Briggs, A.H. , Veestra, D.L. and Sullivan, S.D. (2003) A Bayesian approach to aid in formulary decision making: incorporating institution-specific cost-effectiveness data with clinical trial results. Medical Decision Making, 23(3), pp. 252-264. (doi: 10.1177/0272989X03023003007)
Briggs, A. , Ades, A. and Price, M. (2003) Probabilistic sensitivity analysis for decision trees with multiple branches: use of the Dirichlet distribution in a Bayesian framework. Medical Decision Making, 23(4), pp. 341-350.
Briggs, A. , Clark, T., Wolstenholme, J. and Clark, P. (2003) Missing ... presumed at random: cost analysis of incomplete data. Health Economics, 12(5), pp. 377-393.
Craig, D. et al. (2003) New BMJ policy on economic evaluations. Economic evaluations should be judged on economic merit. British Medical Journal, 326(7386), p. 445.
Hoch, J., Briggs, A. and Willan, A. (2003) Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Economics, 11(5), pp. 415-430.
Hope, A. and Briggs, A. (2003) Concerns regarding the ISPOR Code of Ethics for Researchers. Value in Health, 7(4), pp. 510-511.
Tytgat, G., Heading, R., Muller-Lissner, S., Kamm, M., Scholmerich, J., Berstad, A., Fried, M., Chaussade, S., Jewell, D. and Briggs, A. (2003) Contemporary understanding and management of reflux and constipation in the general population and pregnancy: a consensus meeting. Alimentary Pharmacology and Therapeutics, 18(3), pp. 291-301. (doi: 10.1046/j.1365-2036.2003.01679.x)
Briggs, A. , Clark, T., Wolstenholme, J. and Clarke, P. (2002) Missing.... presumed at random: cost-analysis of incomplete data. Health Economics, 12(5), pp. 377-392. (doi: 10.1002/hec.766)
O'Brien, B.J. and Briggs, A.H. (2002) Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods. Statistical Methods in Medical Research, 11(6), pp. 455-468. (doi: 10.1191/0962280202sm304ra)
Briggs, A.H. , O'Brien, B.J. and Blackhouse, G. (2002) Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annual Review of Public Health, 23, pp. 377-401. (doi: 10.1146/annurev.publhealth.23.100901.140534)
Blackhouse, G., Briggs, A. and O'Brien, B.J. (2002) A note on the estimation of confidence intervals for cost-effectiveness when costs and effects are censored. Medical Decision Making, 22(2), pp. 173-177. (doi: 10.1177/02729890222063053)
Blackhouse, G., Briggs, A. and O'Brien, B. (2002) Estimation of confidence intervals for cost-effectiveness when costs and effects are censored. Medical Decision Making, 22, pp. 170-174.
Blackhouse, G., Briggs, A. and O'Brien, B. (2002) A note on the estimation of confidence intervals for cost-effectiveness when costs and effects are censored. Medical Decision Making, 22(2), pp. 173-177.
Briggs, A.H. , Goeree, R., Blackhouse, G. and O'Brien, B.J. (2002) Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Medical Decision Making, 22(4), pp. 290-308. (doi: 10.1177/027298902400448867)
Briggs, A. , Goeree, R. and O'Brien, B. (2002) Probabilistic analysis of models: choosing between treatment strategies for gastroesophageal reflux disease. Medical Decision Making, 22(4), pp. 290-308.
Briggs, A. , O'Brien, B. and Blackhouse, G. (2002) Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annual Review of Public Health, 23, pp. 377-401.
Goeree, R., O'Brien, B., Blackhouse, G., Marshall, J., Briggs, A. and Lad, R. (2002) Cost-effectiveness and cost-utility of long-term management strategies for heartburn. Value in Health, 5(4), pp. 312-328.
O'Brien, B. and Briggs, A. (2002) Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods. Statistical Methods in Medical Research, 11(6), pp. 455-468.
Price, M.J. and Briggs, A.H. (2002) Development of an economic model to assess the cost effectiveness of asthma management strategies. PharmacoEconomics, 20(3), pp. 183-194.
Sendi, P.P. and Briggs, A.H. (2001) Affordability and cost-effectiveness: decision-making on the cost-effectiveness plane. Health Economics, 10(7), pp. 675-680. (doi: 10.1002/hec.639)
Briggs, A.H. and O'Brien, B.J. (2001) The death of cost-minimization analysis? Health Economics, 10(2), pp. 179-184. (doi: 10.1002/hec.584)
Briggs, A. (2001) A Bayesian approach to stochastic cost-effectiveness analysis. International Journal of Technology Assessment in Health Care, 17(1), pp. 69-82.
Briggs, A. (2001) A Bayesian approach to stochastic cost-effectiveness analysis. An illustration and application to blood pressure control in type 2 diabetes. International Journal of Technology Assessment in Health Care, 17(1), pp. 69-82.
Briggs, A. and O'Brien, B. (2001) The death of cost-minimization analysis?. [23 refs]. Health Economics, 10(2), pp. 179-184.
Briggs, A. and Tambour, M. (2001) The design and analysis of stochastic cost-effectiveness studies for the evaluation of health care interventions. Drug Information Journal, 35(4), pp. 1455-1468.
Delaney, B.C., Wilson, S.L., Roalfe, A., Briggs, A.H. and Hobbs, F.D.R. (2001) Empirical treatment or prompt endoscopy? - author's reply. Lancet, 357, p. 1366. (doi: 10.1016/S0140-6736(00)04492-5)
Glick, H. and Briggs, A. (2001) Cost-effectiveness of health care interventions: a guide to quantifying stochastic uncertainty and presenting the result of cost-effectiveness analyses. Expert Reviews in Pharmacoeconomics and Outcomes Research, 1(1), pp. 25-36.
Levy, A., Briggs, A. , Demers, C. and O'Brien, B. (2001) Cost-effectiveness of beta-blocker therapy with metoprolol or with carvedilol for treatment of heart failure in Canada. American Heart Journal, 142(3), pp. 537-543.
Book Sections
Briggs, A. (2014) Statistical issues in economic evaluations. In: Culyer, A. J. (ed.) Encyclopedia of Health Economics. Elsevier, pp. 352-361. ISBN 9780123756787 (doi: 10.1016/B978-0-12-375678-7.01418-8)
Boyd, K. and Briggs, A. (2013) Statistical issues with trial data and economic modeling for cost-effectiveness evaluation. In: Tang, W. and Tu, X. (eds.) Modern Clinical Trial Analysis. Series: Applied bioinformatics and biostatistics in cancer research. Springer-Verlag: New York, NY, USA, pp. 149-166. ISBN 9781461443216 (doi: 10.1007/978-1-4614-4322-3_6)
Briggs, A. , Starkie, H. and Wu, O. (2009) Health economics in asthma and COPD. In: Barnes, P.J., Drazen, J.M., Rennard, S.I. and Thomson, N.C. (eds.) Asthma and COPD. Academic Press/Elsevier: London, pp. 751-760. ISBN 9780123740014
Research Reports or Papers
Grieve, E. and Briggs, A. (2017) A Methodological Approach for Measuring the Impact of HTA. Technical Report. F1000Research. (doi: 10.7490/f1000research.1113738.1).
Conference or Workshop Item
Grieve, E. , Hesselgreaves, H., Wu, O. and Briggs, A. (2021) Bridging the Perceived Disconnect between Health Technology Assessment and Delivery Systems. 2021 World Congress on Health Economics, 12-15 Jul 2021.
Price, D.B. et al. (2018) Use of 'Low-Dose' Theophylline to Reduce Exacerbations of COPD: a Pragmatic Multicentre Randomised Placebo Controlled Trial. ATS 2018 International Conference, San Diego, CA, USA, 18-23 May 2018.
Kohli-Lynch, C.N. , Boyd, K. , Briggs, A. and Delles, C. (2017) A Framework for the Cost-Effectiveness Analysis of Novel Biomarker Testing in Cardiovascular Disease. ISPOR 20th Annual European Congress, Glasgow, UK, 4-8 Nov 2017. A404-A405. (doi: 10.1016/j.jval.2017.08.040)
McMeekin, N., Briggs, A. and Wu, O. (2017) Developing A Conceptual Modelling Framework For Economic Evaluation. ISPOR 20th Annual European Congress, Glasgow, UK, 4-8 Nov 2017. A754-A755. (doi: 10.1016/j.jval.2017.08.2120)
Conference Proceedings
Paul, J. , Briggs, A. , Harking, A., Hayclon, M., Iveson, T., Masterson, M., Midgley, A. and Cassidy, J. (2006) SCOT: short course oncology therapy — a comparison of 12 and 24 weeks of adjuvant chemotherapy in colorectal cancer. In: 2011 ASCO Annual Meeting, Chicago, Ill, USA, 3-7 Jun 2011, e14145.
Grants
Grants and Awards listed are those received whilst working with the University of Glasgow.
- Randomised control trial of surveillance and no surveillance for patients with Barrett's oesophagus
National Institute for Health Research
2023 - 2024
- The conundrum of angina in patients without obstructive coronary disease
British Heart Foundation
2020 - 2021
- The BHF FAMOUS-NSTEMI long-term follow-up study
British Heart Foundation
2019 - 2021
- BALLAD- A global study to evaluate the potential benefit of adjuvant chemotherapy for small bowel andenocarcinoma (International Rare Cancers Initiative study-IRCI 002)
Cancer Research UK (CRUK)
2018 - 2019
- BALLAD- A global study to evaluate the potential benefit of adjuvant chemotherapy for small bowel andenocarcinoma (International Rare Cancers Initiative study-IRCI 002)
Cancer Research UK
2018 - 2020
- CORonary MICrovascular Angina (CorMicA): a pilot trial with a nested MRI sub-study
British Heart Foundation
2017 - 2020
- The conundrum of angina in patients without obstructive coronary disease: a randomised controlled pilot trial of routine testing of coronary function.
British Heart Foundation
2017 - 2020
- EMPOWER: Early Signs Monitoring to Prevent Relapse and Promote Wellbeing, Engagement and Recovery
National Institute for Health Research
2016 - 2018
- Glasgow Molecular Pathology (GMP) Node
Medical Research Council
2015 - 2019
- Cardiac biomarkers and the prediction of CVD in Scotland
Chief Scientist Office
2015 - 2018
- Establishing priority-setting institutions in developing countries: International Decision Support Initiative
Bill and Melinda Gates Foundation
2015 - 2016
- Symptoms, quality of life and place of care study
British Heart Foundation
2015 - 2016
- PATHway
European Commission
2015 - 2018
- ...the Football Fans in Training follow up RCT (full title in Abstract)
National Institute for Health Research
2015 - 2017
- IDSI-International Decision Support Initiative
Bill and Melinda Gates Foundation
2014 - 2015
- Reducing alcohol consumption in Obese Men - Development and Feasibility Testing of a Complex Community-based Intervention. Your reference: 4909b_CRT
National Institute for Health Research
2014 - 2016
- Evaluation of Health in Pregnancy Grants Scotland.
National Institute for Health Research
2014 - 2015
- BALLAD - A global study to evaluate the potential benefit of adjuvant chemotherapy for small bowel adenocarcinoma.
Cancer Research UK
2013 - 2018
- CULPRIT-SHOCK
European Commission
2013 - 2017
- A randomised, double-blind placebo controlled trial of the effectiveness of low dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of COPD
National Institute for Health Research
2013 - 2017
- Health Economics Assessment of GOLD acute Stroke Technology
Chief Scientist Office
2013 - 2013
- A Parallel group Randomised Open Blinded Evaluation of Acceptance and Commitment Therapy for Depression After Psychosis: A Pilot Trial (ADAPT)
Chief Scientist Office
2013 - 2015
- Cardiac biomarkers and CVD risk screening: a cost-effective public health measure?
British Heart Foundation
2013 - 2016
- The Scottish eHealth Informatics Research Centre (E-HIRCs).
Medical Research Council
2013 - 2018
- Scottish Alcoholic Liver Disease Evaluation of epidemiology and costs of first and subsequent hospital admissions (SCALE)
Chief Scientist Office
2013 - 2015
- BEAT-IT: A randomised controlled trial comparing a behavioural activation treatment for depression in adults with learning disabilities with an attention control
National Institute for Health Research
2013 - 2017
- Autism and Reactive Attachment Disorder symptons in the Scottish Population: associations with health and service use.
Chief Scientist Office
2012 - 2013
- Costs and complications of diabetes - investigation in a comprehensive national diabetes register
Medical Research Council
2012 - 2015
- Randomized open label study of oral versus intravenous antibiotic treatment for bone and joint infections requiring prolonged antibiotic treatment: Multi-centre study.
National Institute for Health Research
2012 - 2017
- How effective is the Forestry Commission Scotland's woodland improvement programme - 'Woods In and Around Towns' (WIAT) - at improving psychological wellbeing in deprived communities?
National Institute for Health Research
2012 - 2017
- SurgiCal Obesity Treatment Study (SCOTS)
National Institute for Health Research
2012 - 2026
- EU-MASCARA - Biomarkers for Cardiovascular Disease
European Commission
2011 - 2015
- Fractional Flow Reserve versus Angiographically Guided Management to Optimise Outcomes in Unstable Coronary Syndromes: a Developmental Clinical Study
British Heart Foundation
2011 - 2014
- A pre-trial model of the cost-effectiveness of fractional flow reserve measurement in NSTEMI
Chief Scientist Office
2011 - 2012
- TEAM-HF
National Institutes of Health
2011 - 2012
- A randomised controlled trial of deferred androgen deprivation therapy +/- upfront cryotherapy in men with localised radiation recurrent prostate cancer (RRPC) to evaluate efficacy and tolerability
Cancer Research UK
2011 - 2013
- How do you plan NHS weight management services? Who are the eligible population and who benefits most?
NHS Education for Scotland
2011 - 2014
- Health Economics
Medical Research Council
2011 - 2015
- Biological, demographic, cognitive and social determinants of health outcomes in older people: results from within-study and extended follow-up of the PROSPER trial.
Chief Scientist Office
2010 - 2013
- Assessing methods to specify the targeted difference for a randomised controlled trial (the DELTA Study)
Medical Research Council
2010 - 2011
- Respiratory Health Economic Evaluation
BUPA Medical Foundation
2010 - 2010
- Evaluation of electrocardiographic monitoring strategy to identify atrial fibrillation in patients with recent acute stroke
Chief Scientist Office
2010 - 2011
- Comparison of close contact cast (CCC) technique to open surgical internal fixation (ORIF) in the treatment of unstable ankle fractures in patients over 60 years
National Coordinating Cent for Health Tech Assessment
2010 - 2017
- From absolute risk to absolute benefit in the prevention of cardiovascular disease: a cardiovascular policy model for Scotland (ASSIGN Plus)
Scottish Executive Health Department
2009 - 2011
- Scottish Health Informatics Programme ( SHIP )
Wellcome Trust
2009 - 2014
- BOSS trial
National Coordinating Cent for Health Tech Assessment
2009 - 2022
- A pilot study to examine the epidemiology of Chronic Obstructive Pulmonary Disease (COPD) in Scotland
Scottish Executive Health Department
2008 - 2009
- Economic impact of Glasgow Keep Well
NHS Health Scotland
2007 - 2008
- Outcome measures for the assessment of treatment results in Chronic Obstructive Pulmonary disease
Office of Health Economics
2007 - 2007
- Comparing models of smoking treatment in Glasgow
Glasgow Centre for Population Health
2007 - 2009
- SCOT - short course oncology therapy - a study of adjuvant chemotherapy in colorectal cancer by the CACTUS & QUASAR 3 groups
Medical Research Council
2007 - 2015
- M-Echo Project
Oxford Radcliffe Hospitals NHS Trust
2007 - 2007
- HOPEFUL Study
Department of Health
2006 - 2006
Research datasets
2019
Paul, J. , Boyd, K. , Briggs, A. , Cassidy, J., Harkin, A. and Iveson, T. (2019) The 'Short Course Oncology Treatment' (SCOT) trial. [Data Collection]